CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | lead diacetate |
|
Accession: | CHEBI:31767
|
browse the term
|
Definition: | A lead coordination entity in which a central lead(2+) atom is coordinated to two acetate ions. |
Synonyms: | exact_synonym: | bis(acetato-kappa(2)O,O')lead; lead(2+) acetate; lead(2+) diacetate; lead(II) acetate |
| related_synonym: | Blei(II)-azetat; Bleidiacetat; Bleidiazetat; Bleizucker; Formula=2C2H3O2.Pb; Formula=C4H6O4Pb; Goulard powder; InChI=1S/2C2H4O2.Pb/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2; InChIKey=GUWSLQUAAYEZAF-UHFFFAOYSA-L; SMILES=CC1=[O][Pb]2(O1)OC(C)=[O]2; acetate de plomb; acetic acid lead salt; acetic acid lead(2+) salt; lead acetate; lead acetate (anhydrous); lead di(acetate); lead dibasic acetate; plumbous acetate; salt of Saturn; sugar of Saturn; sugar of lead |
| xref: | Beilstein:1099661; Beilstein:6919265; CAS:301-04-2; Chemspider:8956; Gmelin:1042008; Gmelin:21797; Gmelin:327405; KEGG:D01945 |
| xref_mesh: | MESH:C008261 |
| xref: | PMID:1894216; PMID:19133285; PMID:21582050; PMID:21582051; PMID:21588188; PMID:25042713; PMID:25052592; PMID:25303036; PMID:27411820; PMID:27548299; PMID:32218311; PMID:32407153; PMID:33088349; PMID:33140846; PMID:33280449; PMID:33498064; PMID:33642811; PMID:33713589; PMID:33754266; PMID:33844168; PMID:4470991; Wikipedia:Lead(II)_acetate |
|
|
|
G |
A2m |
alpha-2-macroglobulin |
affects expression decreases expression |
EXP |
lead acetate affects the expression of A2M mRNA lead acetate results in decreased expression of A2M mRNA |
CTD |
PMID:21864555 PMID:22641619 |
|
NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786
|
|
G |
Aadat |
aminoadipate aminotransferase |
increases expression |
EXP |
lead acetate results in increased expression of AADAT mRNA |
CTD |
PMID:22641619 |
|
NCBI chr16:29,509,392...29,544,332
Ensembl chr16:29,509,394...29,544,332
|
|
G |
Aars1 |
alanyl-tRNA synthetase 1 |
increases expression |
EXP |
lead acetate results in increased expression of AARS mRNA |
CTD |
PMID:11578147 |
|
NCBI chr19:38,999,130...39,021,152
Ensembl chr19:38,999,163...39,021,147
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
EXP |
lead acetate results in increased expression of ABCA1 mRNA; lead acetate results in increased expression of ABCA1 protein |
CTD |
PMID:29908845 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases expression affects export |
EXP ISO |
lead acetate results in increased expression of ABCC1 mRNA; lead acetate results in increased expression of ABCC1 protein ABCC1 protein affects the export of lead acetate |
CTD |
PMID:23274417 PMID:24598511 PMID:27236077 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abce1 |
ATP binding cassette subfamily E member 1 |
increases expression |
EXP |
lead acetate results in increased expression of ABCE1 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr19:28,205,566...28,230,489
Ensembl chr19:28,205,555...28,230,489
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases expression |
EXP |
lead acetate results in increased expression of ABCG2 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abhd15 |
abhydrolase domain containing 15 |
increases expression |
ISO |
lead acetate results in increased expression of ABHD15 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr10:62,363,209...62,368,600
Ensembl chr10:62,363,209...62,368,600
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
decreases expression |
ISO |
lead acetate results in decreased expression of ACACA mRNA |
CTD |
PMID:33932463 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acan |
aggrecan |
increases expression multiple interactions |
ISO |
lead acetate results in increased expression of ACAN mRNA BMP2 promotes the reaction [lead acetate results in increased expression of ACAN mRNA]; lead acetate promotes the reaction [BMP2 results in increased expression of ACAN mRNA] |
CTD |
PMID:17805416 |
|
NCBI chr 1:132,981,034...133,044,416
Ensembl chr 1:132,981,582...133,043,627
|
|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
decreases expression |
ISO |
lead acetate results in decreased expression of ACAT1 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
decreases expression |
ISO |
lead acetate results in decreased expression of ACAT2 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821
|
|
G |
Ace |
angiotensin I converting enzyme |
affects expression |
EXP |
lead acetate affects the expression of ACE mRNA |
CTD |
PMID:21864555 PMID:22641619 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
decreases expression |
ISO |
lead acetate results in decreased expression of ACE2 mRNA |
CTD |
PMID:22613225 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Acer2 |
alkaline ceramidase 2 |
increases expression |
EXP |
lead acetate results in increased expression of ACER2 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 5:101,391,830...101,442,615
Ensembl chr 5:101,391,885...101,442,614
|
|
G |
Ache |
acetylcholinesterase |
decreases expression decreases activity increases activity multiple interactions |
ISO EXP |
lead acetate results in decreased expression of ACHE protein lead acetate results in decreased activity of ACHE protein lead acetate results in increased activity of ACHE protein Biological Factors inhibits the reaction [lead acetate results in decreased activity of ACHE protein]; ferulic acid inhibits the reaction [lead acetate results in increased activity of ACHE protein]; Plant Preparations inhibits the reaction [lead acetate results in decreased activity of ACHE protein] puerarin inhibits the reaction [lead acetate results in decreased expression of ACHE protein] |
CTD |
PMID:23501611 PMID:25322819 PMID:30703413 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acin1 |
apoptotic chromatin condensation inducer 1 |
decreases expression |
ISO |
lead acetate results in decreased expression of ACIN1 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr15:28,102,112...28,147,001
Ensembl chr15:28,102,112...28,147,001
|
|
G |
Acot7 |
acyl-CoA thioesterase 7 |
increases expression |
ISO |
lead acetate results in increased expression of ACOT7 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 5:162,686,562...162,779,309
Ensembl chr 5:162,684,645...162,779,309
|
|
G |
Acsm3 |
acyl-CoA synthetase medium-chain family member 3 |
affects expression |
EXP |
lead acetate affects the expression of ACSM3 mRNA |
CTD |
PMID:21864555 |
|
NCBI chr 1:174,133,260...174,159,966
Ensembl chr 1:174,133,288...174,160,184
|
|
G |
Acsm5 |
acyl-CoA synthetase medium-chain family member 5 |
decreases expression |
EXP |
lead acetate results in decreased expression of ACSM5 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 1:173,870,873...173,896,838
Ensembl chr 1:173,863,041...173,898,588
|
|
G |
Actb |
actin, beta |
affects expression |
ISO |
lead acetate affects the expression of ACTB protein |
CTD |
PMID:20797405 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Acvrl1 |
activin A receptor like type 1 |
increases expression |
ISO |
lead acetate results in increased expression of ACVRL1 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 7:132,239,200...132,256,592
Ensembl chr 7:132,239,729...132,256,591
|
|
G |
Acyp2 |
acylphosphatase 2 |
decreases expression |
ISO |
lead acetate results in decreased expression of ACYP2 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr14:104,201,894...104,371,415
Ensembl chr14:104,201,895...104,371,386
|
|
G |
Adam19 |
ADAM metallopeptidase domain 19 |
decreases expression |
ISO |
lead acetate results in decreased expression of ADAM19 mRNA |
CTD |
PMID:22613225 |
|
NCBI chr10:30,491,362...30,583,115
Ensembl chr10:30,491,405...30,583,105
|
|
G |
Adam1a |
ADAM metallopeptidase domain 1a |
increases expression |
EXP |
lead acetate results in increased expression of ADAM1A mRNA |
CTD |
PMID:22641619 |
|
NCBI chr12:35,017,433...35,020,300
Ensembl chr12:35,017,315...35,020,311
|
|
G |
Adam2 |
ADAM metallopeptidase domain 2 |
increases methylation |
EXP |
lead acetate results in increased methylation of ADAM2 gene |
CTD |
PMID:29571894 |
|
NCBI chr15:40,242,783...40,284,025
Ensembl chr15:40,242,783...40,283,952
|
|
G |
Adam32 |
ADAM metallopeptidase domain 32 |
increases expression |
EXP |
lead acetate results in increased expression of ADAM32 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr16:67,102,384...67,212,163
Ensembl chr16:67,102,320...67,212,161
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
decreases expression |
EXP |
lead acetate results in decreased expression of ADAMTS1 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adamts15 |
ADAM metallopeptidase with thrombospondin type 1 motif, 15 |
decreases expression |
ISO |
lead acetate results in decreased expression of ADAMTS15 mRNA |
CTD |
PMID:22613225 |
|
NCBI chr 8:29,307,864...29,331,249
Ensembl chr 8:29,307,865...29,331,249
|
|
G |
Adamts20 |
ADAM metallopeptidase with thrombospondin type 1 motif, 20 |
increases expression |
EXP |
lead acetate results in increased expression of ADAMTS20 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 7:125,396,227...125,528,020
Ensembl chr 7:125,397,734...125,527,777
|
|
G |
Adamts4 |
ADAM metallopeptidase with thrombospondin type 1 motif, 4 |
increases expression |
EXP |
lead acetate results in increased expression of ADAMTS4 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065
|
|
G |
Adamtsl1 |
ADAMTS-like 1 |
increases expression |
ISO |
lead acetate results in increased expression of ADAMTSL1 mRNA |
CTD |
PMID:20542052 PMID:22613225 |
|
NCBI chr 5:99,964,406...100,919,786
Ensembl chr 5:99,964,486...100,918,384
|
|
G |
Adcy8 |
adenylate cyclase 8 |
increases expression |
ISO EXP |
lead acetate results in increased expression of ADCY8 mRNA |
CTD |
PMID:11578147 PMID:20542052 |
|
NCBI chr 7:96,417,310...96,665,911
Ensembl chr 7:96,417,324...96,665,911
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
decreases expression |
ISO |
lead acetate results in decreased expression of ADCYAP1 mRNA |
CTD |
PMID:22613225 |
|
NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773
|
|
G |
Adgre4 |
adhesion G protein-coupled receptor E4 |
affects expression |
ISO |
lead acetate affects the expression of ADGRE4 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 9:9,758,106...9,901,908
Ensembl chr 9:9,760,355...9,900,760
|
|
G |
Adgrf2 |
adhesion G protein-coupled receptor F2 |
increases expression |
EXP |
lead acetate results in increased expression of ADGRF2 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 9:18,238,389...18,248,745
Ensembl chr 9:18,219,714...18,269,038
|
|
G |
Adgrg6 |
adhesion G protein-coupled receptor G6 |
increases expression |
EXP |
lead acetate results in increased expression of ADGRG6 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 1:8,812,889...8,954,239
Ensembl chr 1:8,812,904...8,954,123
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression |
EXP |
lead acetate results in decreased expression of ADIPOQ mRNA |
CTD |
PMID:11578147 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adipor2 |
adiponectin receptor 2 |
increases expression |
ISO |
lead acetate results in increased expression of ADIPOR2 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 4:152,524,604...152,588,848
Ensembl chr 4:152,524,623...152,559,355
|
|
G |
Adk |
adenosine kinase |
decreases expression |
ISO |
lead acetate results in decreased expression of ADK mRNA |
CTD |
PMID:20542052 |
|
NCBI chr15:2,863,241...3,246,453
Ensembl chr15:2,863,244...3,246,510
|
|
G |
Adora1 |
adenosine A1 receptor |
multiple interactions increases expression |
EXP |
[lead acetate co-treated with Morphine] results in increased expression of ADORA1 mRNA; [lead acetate co-treated with Morphine] results in increased expression of ADORA1 protein; [lead acetate results in increased expression of ADORA1 protein] which results in increased abundance of Adenosine lead acetate results in increased expression of ADORA1 mRNA; lead acetate results in increased expression of ADORA1 protein |
CTD |
PMID:20932874 PMID:26478469 |
|
NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801
|
|
G |
Adpgk |
ADP-dependent glucokinase |
decreases expression |
EXP |
lead acetate results in decreased expression of ADPGK mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 8:59,699,400...59,727,352
Ensembl chr 8:59,699,388...59,727,351
|
|
G |
Adra1d |
adrenoceptor alpha 1D |
increases expression |
ISO |
lead acetate results in increased expression of ADRA1D mRNA |
CTD |
PMID:22613225 |
|
NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354
|
|
G |
Adra2b |
adrenoceptor alpha 2B |
increases expression |
ISO |
lead acetate results in increased expression of ADRA2B mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 3:114,585,174...114,589,220
Ensembl chr 3:114,585,169...114,589,355
|
|
G |
Adtrp |
androgen-dependent TFPI-regulating protein |
increases expression |
ISO |
lead acetate results in increased expression of ADTRP mRNA |
CTD |
PMID:22609695 |
|
NCBI chr17:22,930,012...22,993,834
Ensembl chr17:22,930,740...22,993,826
|
|
G |
Aebp1 |
AE binding protein 1 |
increases expression |
EXP |
lead acetate results in increased expression of AEBP1 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr14:80,738,800...80,748,878
Ensembl chr14:80,738,892...80,748,877
|
|
G |
Ahnak |
AHNAK nucleoprotein |
increases expression |
ISO |
lead acetate results in increased expression of AHNAK mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 1:205,882,223...205,970,934
Ensembl chr 1:205,882,273...205,970,926
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases expression multiple interactions |
EXP ISO |
lead acetate results in increased expression of AHR mRNA; lead acetate results in increased expression of AHR protein [Cadmium Chloride co-treated with Benzo(a)pyrene co-treated with lead acetate] results in increased activity of AHR protein; [lead acetate co-treated with Benzo(a)pyrene] results in increased activity of AHR protein; [sodium arsenite co-treated with Benzo(a)pyrene co-treated with lead acetate] results in increased activity of AHR protein |
CTD |
PMID:17576166 PMID:29502740 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ahsp |
alpha hemoglobin stabilizing protein |
affects expression |
EXP |
lead acetate affects the expression of AHSP mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 1:182,879,901...182,885,508
Ensembl chr 1:182,880,076...182,885,506
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
increases expression decreases expression multiple interactions |
ISO EXP |
lead acetate results in increased expression of AIF1 mRNA lead acetate results in decreased expression of AIF1 mRNA [lead acetate co-treated with Morphine] results in increased expression of AIF1 mRNA |
CTD |
PMID:21829687 PMID:26478469 PMID:33862172 |
|
NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
affects expression multiple interactions decreases expression |
EXP ISO |
lead acetate affects the expression of AIFM1 protein [lead acetate results in increased abundance of Lead] which results in increased expression of AIFM1 protein; PPIF protein affects the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of AIFM1 protein] lead acetate results in decreased expression of AIFM1 mRNA |
CTD |
PMID:18618274 PMID:23146751 PMID:31874198 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Aipl1 |
aryl hydrocarbon receptor-interacting protein-like 1 |
decreases expression |
EXP |
lead acetate results in decreased expression of AIPL1 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr10:56,655,693...56,664,922
Ensembl chr10:56,655,693...56,664,922
|
|
G |
Akap7 |
A-kinase anchoring protein 7 |
increases expression |
ISO |
lead acetate results in increased expression of AKAP7 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 1:20,087,190...20,217,799
Ensembl chr 1:20,087,373...20,217,797
|
|
G |
Akap8 |
A-kinase anchoring protein 8 |
increases methylation |
EXP |
lead acetate results in increased methylation of AKAP8 gene |
CTD |
PMID:29571894 |
|
NCBI chr 7:11,316,224...11,332,523
Ensembl chr 7:11,316,228...11,332,399
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
increases expression |
ISO |
lead acetate results in increased expression of AKR1C1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
increases expression |
ISO |
lead acetate results in increased expression of AKR1C2 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akr7a3 |
aldo-keto reductase family 7 member A3 |
increases expression |
EXP |
lead acetate results in increased expression of AKR7A3 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO EXP |
lead acetate results in increased phosphorylation of AKT1 protein Genistein inhibits the reaction [lead acetate results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:24530660 PMID:26542248 PMID:26797587 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
increases expression decreases expression |
ISO EXP |
lead acetate results in increased expression of AKT2 mRNA lead acetate results in decreased expression of AKT2 mRNA |
CTD |
PMID:22609695 PMID:30980912 PMID:33932463 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Alad |
aminolevulinate dehydratase |
decreases expression multiple interactions decreases activity |
EXP ISO |
lead acetate results in decreased expression of ALAD protein Ditiocarb inhibits the reaction [lead acetate results in decreased activity of ALAD protein]; ferulic acid inhibits the reaction [lead acetate results in decreased activity of ALAD protein]; indium trichloride promotes the reaction [lead acetate results in decreased activity of ALAD protein]; lead acetate promotes the reaction [indium trichloride results in decreased activity of ALAD protein]; Vitamin E inhibits the reaction [lead acetate results in decreased activity of ALAD protein] Curcumin inhibits the reaction [lead acetate results in decreased activity of ALAD protein] |
CTD |
PMID:1032310 PMID:2177232 PMID:2604901 PMID:7084431 PMID:22362014 PMID:23292317 PMID:24345272 PMID:24970117 PMID:25322819 More...
|
|
NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474
|
|
G |
Alas2 |
5'-aminolevulinate synthase 2 |
increases expression |
EXP |
lead acetate results in increased expression of ALAS2 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr X:19,463,146...19,486,526
Ensembl chr X:19,463,171...19,486,519
|
|
G |
Alb |
albumin |
increases expression multiple interactions |
EXP |
lead acetate results in increased expression of ALB mRNA; lead acetate results in increased expression of ALB protein [sodium arsenite co-treated with Cadmium Chloride co-treated with lead acetate co-treated with Mercuric Chloride co-treated with chromium trioxide co-treated with nickel chloride co-treated with manganese chloride co-treated with ferric chloride] results in decreased expression of ALB protein |
CTD |
PMID:17657459 PMID:21549428 PMID:22641619 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alcam |
activated leukocyte cell adhesion molecule |
increases expression |
ISO |
lead acetate results in increased expression of ALCAM mRNA |
CTD |
PMID:21829687 |
|
NCBI chr11:48,336,123...48,536,296
Ensembl chr11:48,336,169...48,537,954
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases expression |
ISO |
lead acetate results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh1l2 |
aldehyde dehydrogenase 1 family, member L2 |
increases expression |
ISO |
lead acetate results in increased expression of ALDH1L2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:20,254,196...20,305,793
Ensembl chr 7:20,254,233...20,305,776
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
EXP |
[lead acetate results in increased abundance of Lead] affects the reaction [Ethanol affects the expression of ALDH2 protein]; [lead acetate results in increased abundance of Lead] which affects the expression of ALDH2 protein; Cyanamide affects the reaction [[lead acetate results in increased abundance of Lead] affects the reaction [Ethanol affects the expression of ALDH2 protein]]; Cyanamide affects the reaction [[lead acetate results in increased abundance of Lead] which affects the expression of ALDH2 protein] |
CTD |
PMID:31550440 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Aldh7a1 |
aldehyde dehydrogenase 7 family, member A1 |
increases expression |
ISO |
lead acetate results in increased expression of ALDH7A1 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr18:50,003,242...50,042,193
Ensembl chr18:50,009,934...50,042,193
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
increases expression |
ISO |
lead acetate results in increased expression of ALDOA protein |
CTD |
PMID:20797405 |
|
NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
decreases expression |
ISO |
lead acetate results in decreased expression of ALDOC protein |
CTD |
PMID:20797405 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Alms1 |
ALMS1, centrosome and basal body associated protein |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of ALMS1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 4:118,125,581...118,226,005
Ensembl chr 4:118,125,607...118,226,005
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
decreases expression |
EXP |
lead acetate results in decreased expression of ALOX15 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Aloxe3 |
arachidonate lipoxygenase 3 |
increases expression |
ISO |
lead acetate results in increased expression of ALOXE3 mRNA |
CTD |
PMID:22613225 |
|
NCBI chr10:53,830,219...53,854,328
Ensembl chr10:53,831,264...53,854,328
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
decreases expression |
EXP |
lead acetate results in decreased expression of ALPL protein |
CTD |
PMID:21712424 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Alx3 |
ALX homeobox 3 |
decreases methylation |
EXP |
lead acetate results in decreased methylation of ALX3 gene |
CTD |
PMID:29571894 |
|
NCBI chr 2:195,231,197...195,241,609
Ensembl chr 2:195,231,197...195,241,609
|
|
G |
Amy1 |
amylase alpha 1 |
decreases activity |
EXP |
lead acetate results in decreased activity of AMY1 protein |
CTD |
PMID:16510233 |
|
NCBI chr 2:201,382,678...201,397,487
Ensembl chr 2:201,382,675...201,397,816
|
|
G |
Angptl1 |
angiopoietin-like 1 |
decreases expression |
ISO |
lead acetate results in decreased expression of ANGPTL1 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr13:68,963,198...68,969,742
Ensembl chr13:68,962,991...68,992,570
|
|
G |
Ankrd24 |
ankyrin repeat domain 24 |
decreases expression |
ISO |
lead acetate results in decreased expression of ANKRD24 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 7:8,061,634...8,081,142
Ensembl chr 7:8,061,953...8,081,142
|
|
G |
Ankrd33b |
ankyrin repeat domain 33B |
increases expression |
ISO |
lead acetate results in increased expression of ANKRD33B mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:82,277,604...82,359,420
Ensembl chr 2:82,283,108...82,358,872
|
|
G |
Ankrd34a |
ankyrin repeat domain 34A |
decreases expression |
ISO |
lead acetate results in decreased expression of ANKRD34A mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:184,129,830...184,135,075
Ensembl chr 2:184,129,238...184,135,116
|
|
G |
Antxr2 |
ANTXR cell adhesion molecule 2 |
decreases expression |
ISO |
lead acetate results in decreased expression of ANTXR2 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr14:11,542,266...11,682,112
Ensembl chr14:11,541,772...11,682,094
|
|
G |
Anxa1 |
annexin A1 |
decreases expression |
EXP |
lead acetate results in decreased expression of ANXA1 mRNA; lead acetate results in decreased expression of ANXA1 protein |
CTD |
PMID:11578147 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Anxa5 |
annexin A5 |
increases expression multiple interactions |
EXP ISO |
lead acetate results in increased expression of ANXA5 mRNA; lead acetate results in increased expression of ANXA5 protein lead acetate binds to and results in increased activity of ANXA5 protein |
CTD |
PMID:11578147 |
|
NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369
|
|
G |
Ap2a1 |
adaptor related protein complex 2 subunit alpha 1 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of AP2A1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 1:95,384,303...95,414,249
Ensembl chr 1:95,384,309...95,414,147
|
|
G |
Ap3d1 |
adaptor related protein complex 3 subunit delta 1 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of AP3D1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 7:8,970,249...9,005,651
Ensembl chr 7:8,970,291...9,005,643
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression |
ISO |
lead acetate results in increased expression of APAF1 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Apba1 |
amyloid beta precursor protein binding family A member 1 |
multiple interactions |
ISO |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of APBA1 mRNA |
CTD |
PMID:12634122 |
|
NCBI chr 1:221,363,769...221,569,496
Ensembl chr 1:221,363,778...221,566,553
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
multiple interactions increases expression decreases expression decreases response to substance |
ISO EXP |
[lead acetate results in increased expression of APEX1 protein] which results in increased abundance of Reactive Oxygen Species; APEX1 protein promotes the reaction [lead acetate results in increased expression of CCND1 protein]; APEX1 protein promotes the reaction [lead acetate results in increased phosphorylation of MAPK1 protein]; APEX1 protein promotes the reaction [lead acetate results in increased phosphorylation of MAPK3 protein]; lead acetate promotes the reaction [APEX1 protein results in increased phosphorylation of MAPK1 protein]; lead acetate promotes the reaction [APEX1 protein results in increased phosphorylation of MAPK3 protein]; lead acetate promotes the reaction [MAPK1 protein modified form binds to APEX1 protein] lead acetate results in increased expression of APEX1 mRNA lead acetate results in decreased expression of APEX1 mRNA APEX1 protein results in decreased susceptibility to lead acetate |
CTD |
PMID:23370007 PMID:33862172 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Aph1b |
aph-1 homolog B, gamma secretase subunit |
decreases expression |
EXP |
lead acetate results in decreased expression of APH1B mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 8:67,429,198...67,454,735
Ensembl chr 8:67,429,198...67,450,243
|
|
G |
Apobec1 |
apolipoprotein B mRNA editing enzyme catalytic subunit 1 |
decreases expression |
EXP |
lead acetate results in decreased expression of APOBEC1 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 4:155,800,030...155,828,515
Ensembl chr 4:155,800,887...155,827,390
|
|
G |
Apoc2 |
apolipoprotein C2 |
increases expression |
ISO |
lead acetate results in increased expression of APOC2 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 1:79,329,429...79,334,397
Ensembl chr 1:79,329,428...79,334,476
|
|
G |
Apoe |
apolipoprotein E |
increases expression increases methylation |
ISO EXP |
lead acetate results in increased expression of APOE mRNA lead acetate results in increased methylation of APOE gene |
CTD |
PMID:21829687 PMID:29571894 PMID:29746905 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
decreases methylation multiple interactions increases expression |
EXP ISO |
lead acetate results in decreased methylation of APP promoter [lead acetate results in increased abundance of Lead] which results in increased expression of APP mRNA; [lead acetate results in increased abundance of Lead] which results in increased expression of APP protein lead acetate results in increased expression of APP mRNA; lead acetate results in increased expression of APP protein; lead acetate results in increased expression of APP protein alternative form; lead acetate results in increased expression of APP protein modified form lead acetate results in increased expression of APP mRNA; lead acetate results in increased expression of APP protein; lead acetate results in increased expression of APP protein modified form Proanthocyanidins inhibits the reaction [lead acetate results in increased expression of APP protein modified form] [[lead acetate results in increased abundance of Lead] which co-treated with APP protein modified form] results in decreased expression of SYP protein; [lead acetate co-treated with tolfenamic acid] results in decreased expression of APP mRNA; [lead acetate results in increased abundance of Lead] promotes the reaction [[APP protein co-treated with APP protein modified form] results in decreased expression of GAP43 protein]; [lead acetate results in increased abundance of Lead] promotes the reaction [[APP protein co-treated with APP protein modified form] results in decreased expression of SYP protein]; [lead acetate results in increased abundance of Lead] promotes the reaction [APP protein binds to APP protein modified form]; [lead acetate results in increased abundance of Lead] promotes the reaction [APP protein binds to APP protein]; [lead acetate results in increased abundance of Lead] promotes the reaction [APP protein modified form binds to APP protein modified form]; [lead acetate results in increased abundance of Lead] promotes the reaction [APP protein modified form results in decreased expression of GAP43 protein]; [lead acetate results in increased abundance of Lead] promotes the reaction [APP protein modified form results in increased expression of BACE1 protein]; [lead acetate results in increased abundance of Lead] promotes the reaction [APP protein results in decreased expression of GAP43 protein]; [lead acetate results in increased abundance of Lead] promotes the reaction [APP protein results in decreased expression of SYP protein]; [lead acetate results in increased abundance of Lead] promotes the reaction [APP protein results in increased expression of BACE1 protein]; tolfenamic acid inhibits the reaction [lead acetate results in increased expression of APP protein modified form] |
CTD |
PMID:21117136 PMID:22279679 PMID:22764079 PMID:23867794 PMID:24462621 PMID:24806610 PMID:25088297 PMID:29908845 PMID:31730887 PMID:31843630 More...
|
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aprt |
adenine phosphoribosyl transferase |
decreases activity |
EXP ISO |
lead acetate results in decreased activity of APRT protein |
CTD |
PMID:19428946 |
|
NCBI chr19:50,626,436...50,628,404
Ensembl chr19:50,626,202...50,628,431
|
|
G |
Ar |
androgen receptor |
increases expression |
ISO |
lead acetate results in increased expression of AR mRNA |
CTD |
PMID:21829687 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arc |
activity-regulated cytoskeleton-associated protein |
decreases expression |
EXP |
lead acetate results in decreased expression of ARC mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378
|
|
G |
Arfgap2 |
ADP-ribosylation factor GTPase activating protein 2 |
decreases expression |
ISO |
lead acetate results in decreased expression of ARFGAP2 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 3:77,236,305...77,248,445
Ensembl chr 3:77,236,322...77,248,455
|
|
G |
Arfgef2 |
ADP ribosylation factor guanine nucleotide exchange factor 2 |
decreases expression |
ISO |
lead acetate results in decreased expression of ARFGEF2 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 3:155,547,504...155,633,652
Ensembl chr 3:155,547,538...155,630,856
|
|
G |
Arglu1 |
arginine and glutamate rich 1 |
increases expression |
ISO |
lead acetate results in increased expression of ARGLU1 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr16:80,753,300...80,777,350
Ensembl chr16:80,753,315...80,777,349
|
|
G |
Arhgap17 |
Rho GTPase activating protein 17 |
decreases expression |
ISO |
lead acetate results in decreased expression of ARHGAP17 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 1:177,807,579...177,897,027
Ensembl chr 1:177,807,583...177,896,854
|
|
G |
Arhgap24 |
Rho GTPase activating protein 24 |
increases expression |
ISO |
lead acetate results in increased expression of ARHGAP24 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr14:6,800,631...7,184,001
Ensembl chr14:6,800,631...7,183,823
|
|
G |
Arl1 |
ADP-ribosylation factor like GTPase 1 |
decreases expression |
ISO |
lead acetate results in decreased expression of ARL1 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 7:23,120,004...23,131,173
Ensembl chr 7:23,119,589...23,131,898
|
|
G |
Arl8b |
ADP-ribosylation factor like GTPase 8B |
increases expression |
ISO |
lead acetate results in increased expression of ARL8B mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 4:141,748,634...141,792,605
Ensembl chr 4:141,748,587...141,792,596
|
|
G |
Arpin |
actin-related protein 2/3 complex inhibitor |
decreases expression |
EXP |
lead acetate results in decreased expression of ARPIN mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 1:133,864,288...133,873,124
Ensembl chr 1:133,864,265...133,873,124
|
|
G |
Arpp21 |
cAMP regulated phosphoprotein 21 |
decreases expression |
ISO |
lead acetate results in decreased expression of ARPP21 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 8:112,034,636...112,199,273
Ensembl chr 8:112,034,642...112,194,297
|
|
G |
Arrdc4 |
arrestin domain containing 4 |
decreases expression increases expression |
ISO |
lead acetate results in decreased expression of ARRDC4 mRNA lead acetate results in increased expression of ARRDC4 mRNA |
CTD |
PMID:21829687 PMID:22839698 |
|
NCBI chr 1:122,369,355...122,383,351
Ensembl chr 1:122,369,360...122,383,290
|
|
G |
Art3 |
ADP-ribosyltransferase 3 |
increases expression |
ISO |
lead acetate results in increased expression of ART3 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr14:15,637,230...15,719,442
Ensembl chr14:15,637,237...15,665,407
|
|
G |
Arvcf |
ARVCF, delta catenin family member |
decreases expression |
ISO |
lead acetate results in decreased expression of ARVCF mRNA |
CTD |
PMID:22609695 |
|
NCBI chr11:82,588,137...82,645,805
Ensembl chr11:82,587,881...82,645,805
|
|
G |
Asah1 |
N-acylsphingosine amidohydrolase 1 |
increases expression |
ISO |
lead acetate results in increased expression of ASAH1 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr16:50,966,404...50,997,827
Ensembl chr16:50,966,229...51,008,233
|
|
G |
Asb14 |
ankyrin repeat and SOCS box-containing 14 |
decreases expression |
EXP ISO |
lead acetate results in decreased expression of ASB14 mRNA |
CTD |
PMID:22609695 PMID:22641619 |
|
NCBI chr16:2,095,567...2,123,259
Ensembl chr16:2,095,644...2,115,135
|
|
G |
Asb6 |
ankyrin repeat and SOCS box-containing 6 |
increases expression |
ISO |
lead acetate results in increased expression of ASB6 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 3:14,110,628...14,115,276
Ensembl chr 3:14,110,628...14,115,242
|
|
G |
Asb9 |
ankyrin repeat and SOCS box-containing 9 |
increases expression |
ISO |
lead acetate results in increased expression of ASB9 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr X:29,956,576...30,001,436
Ensembl chr X:29,956,576...30,001,105
|
|
G |
Asf1a |
anti-silencing function 1A histone chaperone |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of ASF1A mRNA |
CTD |
PMID:22839698 |
|
NCBI chr20:32,893,962...32,908,808
Ensembl chr20:32,893,573...32,908,808
|
|
G |
Asl |
argininosuccinate lyase |
increases expression |
EXP |
lead acetate results in increased expression of ASL mRNA |
CTD |
PMID:11578147 |
|
NCBI chr12:26,659,664...26,677,136
Ensembl chr12:26,659,565...26,679,662
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
EXP ISO |
lead acetate results in increased expression of ASNS mRNA |
CTD |
PMID:11578147 PMID:25270620 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Aspdh |
aspartate dehydrogenase domain containing |
increases expression |
EXP |
lead acetate results in increased expression of ASPDH mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 1:94,956,327...94,960,722
Ensembl chr 1:94,958,316...94,960,722
|
|
G |
Asph |
aspartate-beta-hydroxylase |
increases expression |
ISO |
lead acetate results in increased expression of ASPH mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 5:22,603,879...22,814,107
Ensembl chr 5:22,603,486...22,813,876
|
|
G |
Aspn |
asporin |
decreases expression |
EXP |
lead acetate results in decreased expression of ASPN mRNA |
CTD |
PMID:22641619 |
|
NCBI chr17:15,079,910...15,104,369
Ensembl chr17:15,080,639...15,104,041
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
decreases expression |
EXP |
lead acetate results in decreased expression of ASS1 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression decreases expression |
EXP ISO |
lead acetate results in increased expression of ATF4 protein lead acetate results in decreased expression of ATF4 mRNA |
CTD |
PMID:22811615 PMID:24260418 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf6 |
activating transcription factor 6 |
increases expression |
EXP ISO |
lead acetate results in increased expression of ATF6 mRNA |
CTD |
PMID:11578147 PMID:21829687 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atf7 |
activating transcription factor 7 |
increases expression |
ISO |
lead acetate results in increased expression of ATF7 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 7:133,660,491...133,750,902
Ensembl chr 7:133,663,294...133,750,848
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions increases phosphorylation |
ISO |
ATM protein affects the reaction [lead acetate results in decreased expression of COX4 protein]; lead acetate promotes the reaction [PINK1 protein binds to ATM protein] lead acetate results in increased phosphorylation of ATM protein |
CTD |
PMID:29660402 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp12a |
ATPase H+/K+ transporting non-gastric alpha2 subunit |
increases expression |
ISO |
lead acetate results in increased expression of ATP12A mRNA |
CTD |
PMID:25270620 |
|
NCBI chr15:30,443,571...30,468,229
Ensembl chr15:30,443,571...30,468,229
|
|
G |
Atp1b2 |
ATPase Na+/K+ transporting subunit beta 2 |
increases expression |
EXP |
lead acetate results in increased expression of ATP1B2 mRNA |
CTD |
PMID:22160880 |
|
NCBI chr10:54,318,698...54,324,933
Ensembl chr10:54,318,701...54,324,933
|
|
G |
Atp6v1a |
ATPase H+ transporting V1 subunit A |
affects expression |
ISO |
lead acetate affects the expression of ATP6V1A protein |
CTD |
PMID:20797405 |
|
NCBI chr11:56,561,444...56,614,694
Ensembl chr11:56,560,974...56,614,694
|
|
G |
Atp6v1b1 |
ATPase H+ transporting V1 subunit B1 |
increases expression |
ISO |
lead acetate results in increased expression of ATP6V1B1 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 4:116,223,799...116,242,475
Ensembl chr 4:116,223,799...116,242,475
|
|
G |
Atp6v1b2 |
ATPase H+ transporting V1 subunit B2 |
increases expression |
EXP ISO |
lead acetate results in increased expression of ATP6V1B2 mRNA |
CTD |
PMID:11578147 PMID:25270620 |
|
NCBI chr16:20,617,515...20,641,651
Ensembl chr16:20,617,518...20,641,745
|
|
G |
Atp6v1e1 |
ATPase H+ transporting V1 subunit E1 |
increases expression |
ISO |
lead acetate results in increased expression of ATP6V1E1 protein |
CTD |
PMID:20797405 |
|
NCBI chr 4:154,022,360...154,044,486
Ensembl chr 4:154,022,358...154,044,584
|
|
G |
Atp6v1h |
ATPase H+ transporting V1 subunit H |
increases expression |
ISO |
lead acetate results in increased expression of ATP6V1H mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 5:14,379,029...14,484,703
Ensembl chr 5:14,378,257...14,537,962
|
|
G |
Atp7a |
ATPase copper transporting alpha |
multiple interactions increases expression decreases expression |
EXP |
ATP7A protein modified form inhibits the reaction [lead acetate binds to HSPA5 protein] lead acetate results in increased expression of ATP7A mRNA lead acetate results in decreased expression of ATP7A mRNA; lead acetate results in decreased expression of ATP7A protein |
CTD |
PMID:10702365 PMID:24316150 PMID:25579025 |
|
NCBI chr X:71,094,144...71,201,550
Ensembl chr X:71,094,202...71,198,354
|
|
G |
Atp9b |
ATPase phospholipid transporting 9B (putative) |
increases expression |
ISO |
lead acetate results in increased expression of ATP9B mRNA |
CTD |
PMID:21829687 |
|
NCBI chr18:74,176,863...74,368,993
Ensembl chr18:74,176,863...74,368,953
|
|
G |
Atxn1 |
ataxin 1 |
decreases expression |
EXP |
lead acetate results in decreased expression of ATXN1 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr17:18,737,491...19,142,360
Ensembl chr17:18,737,533...19,142,360
|
|
G |
Aurka |
aurora kinase A |
increases expression |
ISO |
lead acetate results in increased expression of AURKA mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
|
|
G |
Aurkc |
aurora kinase C |
increases expression |
ISO |
lead acetate results in increased expression of AURKC mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 1:66,843,653...66,864,348
Ensembl chr 1:66,843,653...66,864,386
|
|
G |
B3galt2 |
Beta-1,3-galactosyltransferase 2 |
decreases expression |
ISO |
lead acetate results in decreased expression of B3GALT2 mRNA |
CTD |
PMID:27562236 |
|
NCBI chr13:55,389,406...55,398,419
Ensembl chr13:55,389,406...55,398,419
|
|
G |
B3galt6 |
Beta-1,3-galactosyltransferase 6 |
decreases methylation |
EXP |
lead acetate results in decreased methylation of B3GALT6 gene |
CTD |
PMID:29571894 |
|
NCBI chr 5:166,584,202...166,586,338
Ensembl chr 5:166,584,202...166,586,338
|
|
G |
B3gat2 |
beta-1,3-glucuronyltransferase 2 |
decreases expression |
ISO |
lead acetate results in decreased expression of B3GAT2 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 9:26,167,174...26,250,153
Ensembl chr 9:26,167,174...26,250,153
|
|
G |
B3gnt4 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 4 |
increases expression |
EXP |
lead acetate results in increased expression of B3GNT4 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr12:33,070,221...33,073,904
Ensembl chr12:33,060,416...33,073,854
|
|
G |
B4galnt1 |
beta-1,4-N-acetyl-galactosaminyl transferase 1 |
decreases expression |
ISO |
lead acetate results in decreased expression of B4GALNT1 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 7:62,988,429...62,996,190
Ensembl chr 7:62,988,930...62,996,190
|
|
G |
B4galnt2 |
beta-1,4-N-acetyl-galactosaminyl transferase 2 |
increases expression |
ISO |
lead acetate results in increased expression of B4GALNT2 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr10:80,801,594...80,828,005
Ensembl chr10:80,802,941...80,857,700
|
|
G |
Baat |
bile acid CoA:amino acid N-acyltransferase |
decreases expression |
ISO |
lead acetate results in decreased expression of BAAT mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 5:63,851,668...63,860,641
Ensembl chr 5:63,850,705...63,860,685
|
|
G |
Bace1 |
beta-secretase 1 |
increases expression multiple interactions |
ISO EXP |
lead acetate results in increased expression of BACE1 mRNA; lead acetate results in increased expression of BACE1 protein [lead acetate results in increased abundance of Lead] which results in increased expression of BACE1 mRNA; [lead acetate results in increased abundance of Lead] which results in increased expression of BACE1 protein [lead acetate results in increased abundance of Lead] promotes the reaction [APP protein modified form results in increased expression of BACE1 protein]; [lead acetate results in increased abundance of Lead] promotes the reaction [APP protein results in increased expression of BACE1 protein]; [lead acetate results in increased abundance of Lead] which results in increased expression of BACE1 protein |
CTD |
PMID:23867794 PMID:29908845 PMID:31730887 PMID:31843630 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Bad |
BCL2-associated agonist of cell death |
affects expression |
EXP |
lead acetate affects the expression of BAD protein |
CTD |
PMID:18618274 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bag1 |
BAG cochaperone 1 |
multiple interactions |
ISO |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of BAG1 mRNA |
CTD |
PMID:12634122 |
|
NCBI chr 5:56,068,494...56,081,075
Ensembl chr 5:56,068,494...56,081,075
|
|
G |
Baiap2l1 |
BAR/IMD domain containing adaptor protein 2 like 1 |
decreases expression |
EXP |
lead acetate results in decreased expression of BAIAP2L1 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr12:10,250,434...10,339,937
Ensembl chr12:10,250,473...10,339,928
|
|
G |
Barhl1 |
BarH-like homeobox 1 |
decreases expression |
ISO |
lead acetate results in decreased expression of BARHL1 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 3:12,241,327...12,248,649
Ensembl chr 3:12,241,327...12,248,649
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression affects expression decreases expression |
EXP ISO |
[[lead acetate results in increased abundance of Lead] which co-treated with Carbenoxolone] results in increased expression of BAX protein; [Cadmium Chloride co-treated with lead acetate] results in increased expression of BAX protein; [lead acetate results in increased abundance of Lead] which results in increased expression of BAX protein; [sodium arsenite co-treated with Cadmium Chloride co-treated with lead acetate] results in increased expression of BAX protein; Acetylcysteine affects the reaction [lead acetate results in increased expression of BAX protein]; Ascorbic Acid inhibits the reaction [lead acetate results in increased expression of BAX protein]; Genistein affects the reaction [lead acetate results in increased expression of BAX protein]; lead acetate promotes the reaction [Zinc Oxide results in increased expression of BAX mRNA]; Zinc Oxide promotes the reaction [lead acetate results in increased expression of BAX mRNA] lead acetate results in increased expression of BAX mRNA; lead acetate results in increased expression of BAX protein NFE2L2 protein inhibits the reaction [lead acetate results in increased expression of BAX protein] lead acetate affects the expression of BAX protein lead acetate results in decreased expression of BAX mRNA; lead acetate results in decreased expression of BAX protein |
CTD |
PMID:17959157 PMID:23086308 PMID:23146751 PMID:24960054 PMID:25031709 PMID:26396915 PMID:26498409 PMID:26542248 PMID:26797587 PMID:33242459 PMID:34553816 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbx |
BBX high mobility group box domain containing |
decreases methylation |
EXP |
lead acetate results in decreased methylation of BBX gene |
CTD |
PMID:29571894 |
|
NCBI chr11:50,381,249...50,628,934
Ensembl chr11:50,381,247...50,623,251
|
|
G |
Bcat1 |
branched chain amino acid transaminase 1 |
increases expression |
EXP ISO |
lead acetate results in increased expression of BCAT1 mRNA |
CTD |
PMID:11578147 PMID:25270620 |
|
NCBI chr 4:177,964,834...178,046,573
Ensembl chr 4:177,964,834...178,046,597
|
|
G |
Bccip |
BRCA2 and CDKN1A interacting protein |
decreases expression |
EXP |
lead acetate results in decreased expression of BCCIP mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 1:188,512,544...188,524,957
Ensembl chr 1:188,512,367...188,524,958
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions increases activity |
EXP |
ferulic acid promotes the reaction [lead acetate results in increased activity of BCHE protein] |
CTD |
PMID:25322819 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bcl10 |
BCL10, immune signaling adaptor |
increases expression |
ISO |
lead acetate results in increased expression of BCL10 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 2:234,840,880...234,850,520
Ensembl chr 2:234,840,858...234,850,523
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression affects expression increases expression |
EXP ISO |
[[lead acetate results in increased abundance of Lead] which co-treated with Carbenoxolone] results in decreased expression of BCL2 protein; [Cadmium Chloride co-treated with lead acetate] results in decreased expression of BCL2 protein; [lead acetate results in increased abundance of Lead] which results in decreased expression of BCL2 protein; [sodium arsenite co-treated with Cadmium Chloride co-treated with lead acetate] results in decreased expression of BCL2 protein; Ascorbic Acid promotes the reaction [lead acetate results in increased expression of BCL2 protein]; Genistein inhibits the reaction [lead acetate results in decreased expression of BCL2 protein]; lead acetate promotes the reaction [Zinc Oxide results in decreased expression of BCL2 mRNA]; Zinc Oxide promotes the reaction [lead acetate results in decreased expression of BCL2 mRNA] NFE2L2 protein inhibits the reaction [lead acetate results in decreased expression of BCL2 protein] lead acetate affects the expression of BCL2 protein lead acetate results in decreased expression of BCL2 mRNA; lead acetate results in decreased expression of BCL2 protein lead acetate results in increased expression of BCL2 mRNA lead acetate affects the expression of BCL2 mRNA |
CTD |
PMID:17959157 PMID:18618274 PMID:19026729 PMID:22609695 PMID:23086308 PMID:23146751 PMID:24960054 PMID:25031709 PMID:26396915 PMID:26498409 PMID:26542248 PMID:26797587 PMID:33242459 PMID:34553816 More...
|
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
affects expression multiple interactions |
ISO |
lead acetate affects the expression of BCL2L1 protein HMOX1 protein affects the reaction [lead acetate affects the expression of BCL2L1 protein] |
CTD |
PMID:26542248 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
increases expression |
ISO |
lead acetate results in increased expression of BCL2L11 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bco2 |
beta-carotene oxygenase 2 |
decreases expression |
ISO |
lead acetate results in decreased expression of BCO2 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 8:50,882,174...50,907,676
Ensembl chr 8:50,882,181...50,915,467
|
|
G |
Bdh2 |
3-hydroxybutyrate dehydrogenase 2 |
increases expression |
ISO |
lead acetate results in increased expression of BDH2 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 2:223,702,410...223,723,076
Ensembl chr 2:223,702,412...223,723,072
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions increases expression affects expression decreases expression decreases secretion decreases response to substance |
EXP ISO |
[lead acetate results in increased abundance of Lead] which results in decreased cleavage of BDNF protein; [lead acetate results in increased abundance of Lead] which results in decreased expression of BDNF mRNA; [sodium arsenite co-treated with lead acetate co-treated with Cadmium Chloride] results in decreased expression of BDNF protein; BDNF protein inhibits the reaction [lead acetate results in decreased expression of SYP protein]; BDNF protein inhibits the reaction [lead acetate results in decreased expression of VAMP2 protein]; Resveratrol inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased cleavage of BDNF protein]; Resveratrol inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of BDNF mRNA] lead acetate results in increased expression of BDNF mRNA lead acetate affects the expression of BDNF mRNA alternative form lead acetate results in decreased expression of BDNF mRNA alternative form lead acetate results in decreased expression of BDNF protein lead acetate results in decreased secretion of BDNF protein BDNF protein results in decreased susceptibility to lead acetate |
CTD |
PMID:20375082 PMID:23146751 PMID:23680456 PMID:24260418 PMID:27492863 PMID:27984133 PMID:33862172 PMID:33978298 More...
|
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Becn1 |
beclin 1 |
increases cleavage multiple interactions increases expression |
EXP |
lead acetate results in increased cleavage of BECN1 protein [lead acetate results in increased abundance of Lead] which results in increased expression of BECN1 protein; bafilomycin A1 promotes the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of BECN1 protein] lead acetate results in increased expression of BECN1 protein |
CTD |
PMID:22811615 PMID:32879255 PMID:33242459 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Best3 |
bestrophin 3 |
decreases expression |
EXP |
lead acetate results in decreased expression of BEST3 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 7:52,586,824...52,656,776
Ensembl chr 7:52,615,776...52,656,766
|
|
G |
Bex4 |
brain expressed, X-linked 4 |
increases expression |
EXP |
lead acetate results in increased expression of BEX4 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr X:99,132,076...99,133,413
Ensembl chr X:99,131,942...99,133,531
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions decreases expression |
EXP |
Ethanol promotes the reaction [lead acetate results in decreased expression of BGLAP protein] |
CTD |
PMID:23376407 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bhmt |
betaine-homocysteine S-methyltransferase |
decreases expression |
EXP |
lead acetate results in decreased expression of BHMT mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742
|
|
G |
Bid |
BH3 interacting domain death agonist |
affects expression |
EXP |
lead acetate affects the expression of BID protein |
CTD |
PMID:18618274 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression |
ISO |
lead acetate results in decreased expression of BIRC3 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Bloc1s2 |
biogenesis of lysosomal organelles complex-1, subunit 2 |
increases expression |
EXP |
lead acetate results in increased expression of BLOC1S2 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 1:243,024,611...243,031,749
Ensembl chr 1:243,024,614...243,031,653
|
|
G |
Blvrb |
biliverdin reductase B |
increases expression |
ISO |
lead acetate results in increased expression of BLVRB mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375
|
|
G |
Bmp10 |
bone morphogenetic protein 10 |
increases methylation |
EXP |
lead acetate results in increased methylation of BMP10 gene |
CTD |
PMID:29571894 |
|
NCBI chr 4:119,872,066...119,877,694
Ensembl chr 4:119,872,045...119,878,627
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions decreases expression increases expression increases activity |
ISO EXP |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of BMP2 mRNA lead acetate results in decreased expression of BMP2 mRNA lead acetate results in increased expression of BMP2 mRNA lead acetate results in increased activity of BMP2 protein BMP2 promotes the reaction [lead acetate results in increased expression of ACAN mRNA]; BMP2 promotes the reaction [lead acetate results in increased expression of COL2A1 mRNA]; BMP2 promotes the reaction [lead acetate results in increased expression of SOX9 mRNA]; lead acetate inhibits the reaction [BMP2 protein results in increased phosphorylation of SMAD1 protein]; lead acetate inhibits the reaction [BMP2 protein results in increased phosphorylation of SMAD5 protein]; lead acetate inhibits the reaction [BMP2 protein results in increased phosphorylation of SMAD9 protein]; lead acetate promotes the reaction [BMP2 results in increased expression of ACAN mRNA]; lead acetate promotes the reaction [BMP2 results in increased expression of SOX9 mRNA] |
CTD |
PMID:12634122 PMID:17805416 PMID:21829687 PMID:22641619 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp3 |
bone morphogenetic protein 3 |
decreases expression |
EXP |
lead acetate results in decreased expression of BMP3 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr14:10,712,489...10,737,153
Ensembl chr14:10,712,489...10,737,153
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
multiple interactions decreases expression |
ISO |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in increased expression of BMP4 mRNA lead acetate results in decreased expression of BMP4 mRNA |
CTD |
PMID:12634122 PMID:22613225 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Bpifb3 |
BPI fold containing family B, member 3 |
increases expression |
ISO |
lead acetate results in increased expression of BPIFB3 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 3:142,401,068...142,415,684
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
decreases expression |
ISO |
lead acetate results in decreased expression of BRCA1 mRNA |
CTD |
PMID:22613225 |
|
NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
|
|
G |
Bri3 |
brain protein I3 |
decreases expression |
ISO |
lead acetate results in decreased expression of BRI3 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr12:10,341,007...10,364,655
Ensembl chr12:10,341,011...10,364,735
|
|
G |
Bsg |
basigin (Ok blood group) |
multiple interactions affects expression |
ISO |
[lead acetate results in increased abundance of Lead] which results in decreased expression of BSG protein; [Zinc Acetate results in increased abundance of Zinc] inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of BSG protein]; lead acetate results in decreased expression of and affects the localization of BSG protein lead acetate affects the expression of BSG mRNA |
CTD |
PMID:30615929 PMID:34508822 |
|
NCBI chr 7:9,993,170...10,000,387
Ensembl chr 7:9,993,170...10,000,387
|
|
G |
Bsx |
brain specific homeobox |
decreases expression |
EXP |
lead acetate results in decreased expression of BSX mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 8:41,254,105...41,257,861
Ensembl chr 8:41,254,105...41,257,861
|
|
G |
Btbd1 |
BTB domain containing 1 |
increases expression |
ISO |
lead acetate results in increased expression of BTBD1 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 1:135,734,549...135,773,067
Ensembl chr 1:135,734,589...135,771,981
|
|
G |
Btbd7 |
BTB domain containing 7 |
decreases expression |
ISO |
lead acetate results in decreased expression of BTBD7 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 6:121,920,365...122,010,114
Ensembl chr 6:121,923,023...121,972,405
|
|
G |
Btbd9 |
BTB domain containing 9 |
increases expression |
ISO |
lead acetate results in increased expression of BTBD9 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr20:8,286,337...8,645,567
Ensembl chr20:8,288,711...8,643,960
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
decreases expression |
EXP |
lead acetate results in decreased expression of BTG2 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Btla |
B and T lymphocyte associated |
increases expression |
ISO |
lead acetate results in increased expression of BTLA mRNA |
CTD |
PMID:20542052 |
|
NCBI chr11:55,563,683...55,588,187
Ensembl chr11:55,564,899...55,587,181
|
|
G |
Btnl7 |
butyrophilin-like 7 |
increases expression |
EXP |
lead acetate results in increased expression of BTNL7 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr20:4,301,078...4,313,522
Ensembl chr20:4,301,854...4,313,274
|
|
G |
Bub1 |
BUB1 mitotic checkpoint serine/threonine kinase |
decreases expression |
ISO |
lead acetate results in decreased expression of BUB1 mRNA |
CTD |
PMID:22613225 |
|
NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650
|
|
G |
C2 |
complement C2 |
increases expression |
ISO |
lead acetate results in increased expression of C2 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr20:3,951,474...3,970,376
Ensembl chr20:3,951,474...3,976,505
|
|
G |
C9 |
complement C9 |
decreases expression |
ISO |
lead acetate results in decreased expression of C9 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 2:55,573,094...55,621,345
Ensembl chr 2:55,572,992...55,621,338
|
|
G |
Cables1 |
Cdk5 and Abl enzyme substrate 1 |
increases expression |
EXP |
lead acetate results in increased expression of CABLES1 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr18:3,076,556...3,181,183
Ensembl chr18:3,075,524...3,181,181
|
|
G |
Cacna1b |
calcium voltage-gated channel subunit alpha1 B |
decreases expression |
ISO |
lead acetate results in decreased expression of CACNA1B mRNA |
CTD |
PMID:33932463 |
|
NCBI chr 3:7,380,892...7,546,104
Ensembl chr 3:7,380,922...7,546,091
|
|
G |
Cacna1f |
calcium voltage-gated channel subunit alpha1 F |
decreases expression |
EXP |
lead acetate results in decreased expression of CACNA1F mRNA |
CTD |
PMID:22641619 |
|
NCBI chr X:14,868,096...14,896,413
Ensembl chr X:14,868,024...14,896,413
|
|
G |
Cacna2d1 |
calcium voltage-gated channel auxiliary subunit alpha2delta 1 |
decreases expression |
ISO |
lead acetate results in decreased expression of CACNA2D1 mRNA |
CTD |
PMID:33932463 |
|
NCBI chr 4:18,950,611...19,374,969
Ensembl chr 4:18,951,002...19,374,969
|
|
G |
Cacna2d4 |
calcium voltage-gated channel auxiliary subunit alpha2delta 4 |
decreases expression |
EXP |
lead acetate results in decreased expression of CACNA2D4 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 4:152,408,657...152,524,614
Ensembl chr 4:152,408,657...152,521,268
|
|
G |
Calb1 |
calbindin 1 |
increases expression |
EXP |
lead acetate results in increased expression of CALB1 mRNA |
CTD |
PMID:33862172 |
|
NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431
|
|
G |
Calb2 |
calbindin 2 |
multiple interactions |
EXP |
[lead acetate results in increased abundance of Lead] which results in decreased expression of CALB2 protein; Ascorbic Acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of CALB2 protein] |
CTD |
PMID:31708536 |
|
NCBI chr19:38,114,435...38,141,438
Ensembl chr19:38,114,424...38,141,438
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
decreases expression multiple interactions |
EXP |
lead acetate results in decreased expression of CALCA mRNA; lead acetate results in decreased expression of CALCA protein [Ethanol co-treated with lead acetate] results in increased expression of CALCA protein |
CTD |
PMID:22641619 PMID:23376407 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Cald1 |
caldesmon 1 |
decreases expression |
EXP |
lead acetate results in decreased expression of CALD1 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr 4:63,265,781...63,446,936
Ensembl chr 4:63,265,942...63,446,932
|
|
G |
Calml3 |
calmodulin-like 3 |
increases expression |
EXP |
lead acetate results in increased expression of CALML3 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr17:66,419,844...66,423,083
Ensembl chr17:66,419,882...66,423,175
|
|
G |
Calr |
calreticulin |
decreases expression |
ISO |
lead acetate results in decreased expression of CALR mRNA |
CTD |
PMID:21829687 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Calu |
calumenin |
increases expression |
ISO |
lead acetate results in increased expression of CALU mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
decreases expression multiple interactions decreases phosphorylation |
EXP ISO |
lead acetate results in decreased expression of CAMK2A mRNA [lead acetate results in increased abundance of Lead] which results in increased expression of and results in decreased phosphorylation of CAMK2A protein Quercetin inhibits the reaction [lead acetate results in decreased phosphorylation of CAMK2A protein] |
CTD |
PMID:22160880 PMID:23855546 PMID:30905827 |
|
NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994
|
|
G |
Camk2d |
calcium/calmodulin-dependent protein kinase II delta |
decreases expression multiple interactions |
EXP |
lead acetate results in decreased expression of CAMK2D mRNA [lead acetate results in increased abundance of Lead] which results in decreased expression of CAMK2D mRNA |
CTD |
PMID:22641619 PMID:33080273 |
|
NCBI chr 2:215,023,785...215,287,351
Ensembl chr 2:215,024,004...215,286,178
|
|
G |
Camk2n2 |
calcium/calmodulin-dependent protein kinase II inhibitor 2 |
decreases expression |
ISO |
lead acetate results in decreased expression of CAMK2N2 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr11:80,289,702...80,290,829
|
|
G |
Cand1 |
cullin-associated and neddylation-dissociated 1 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of CAND1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 7:54,681,114...54,719,002
Ensembl chr 7:54,680,900...54,718,993
|
|
G |
Capsl |
calcyphosine-like |
increases expression |
EXP |
lead acetate results in increased expression of CAPSL mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 2:58,394,995...58,425,527
Ensembl chr 2:58,411,424...58,424,980
|
|
G |
Car11 |
carbonic anhydrase 11 |
increases expression |
ISO |
lead acetate results in increased expression of CAR11 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 1:96,169,900...96,175,191
Ensembl chr 1:96,170,080...96,175,191
|
|
G |
Car13 |
carbonic anhydrase 13 |
affects expression |
EXP |
lead acetate affects the expression of CAR13 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 2:86,928,401...86,959,525
Ensembl chr 2:86,928,383...86,959,525
|
|
G |
Car14 |
carbonic anhydrase 14 |
affects expression |
EXP |
lead acetate affects the expression of CAR14 mRNA |
CTD |
PMID:21864555 |
|
NCBI chr 2:183,442,263...183,449,207
Ensembl chr 2:183,441,667...183,449,693
|
|
G |
Car8 |
carbonic anhydrase 8 |
decreases expression |
ISO |
lead acetate results in decreased expression of CAR8 mRNA |
CTD |
PMID:22613225 |
|
NCBI chr 5:21,302,940...21,402,395
Ensembl chr 5:21,305,383...21,402,374
|
|
G |
Card14 |
caspase recruitment domain family, member 14 |
decreases expression |
ISO |
lead acetate results in decreased expression of CARD14 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr10:104,572,059...104,601,606
Ensembl chr10:104,566,424...104,601,905
|
|
G |
Cars |
cysteinyl-tRNA synthetase |
increases expression |
EXP |
lead acetate results in increased expression of CARS mRNA |
CTD |
PMID:11578147 |
|
NCBI chr 1:198,753,689...198,796,016
Ensembl chr 1:198,753,691...198,795,941
|
|
G |
Casp1 |
caspase 1 |
increases expression |
ISO |
lead acetate results in increased expression of CASP1 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
increases expression increases activity increases cleavage multiple interactions affects expression decreases expression |
EXP ISO |
lead acetate results in increased expression of CASP3 mRNA; lead acetate results in increased expression of CASP3 protein lead acetate results in increased activity of CASP3 protein lead acetate results in increased cleavage of CASP3 protein HMOX1 protein affects the reaction [lead acetate affects the expression of CASP3 protein]; NFE2L2 protein inhibits the reaction [lead acetate results in increased activity of CASP3 protein] [Cadmium Chloride co-treated with lead acetate] results in increased expression of CASP3 protein; [lead acetate results in increased abundance of Lead] which results in increased cleavage of CASP3 protein; [lead acetate results in increased abundance of Lead] which results in increased expression of CASP3 protein; [sodium arsenite co-treated with lead acetate co-treated with Cadmium Chloride] results in increased expression of CASP3 protein modified form; Biological Factors inhibits the reaction [lead acetate results in increased expression of CASP3 mRNA]; Biological Factors inhibits the reaction [lead acetate results in increased expression of CASP3 protein]; Carbenoxolone promotes the reaction [[lead acetate results in increased abundance of Lead] which results in increased cleavage of CASP3 protein]; Genistein inhibits the reaction [lead acetate results in increased cleavage of CASP3 protein]; lead acetate promotes the reaction [sodium arsenite results in increased expression of CASP3 mRNA]; monoisoamyl-2,3-dimercaptosuccinate inhibits the reaction [lead acetate promotes the reaction [sodium arsenite results in increased expression of CASP3 mRNA]]; monoisoamyl-2,3-dimercaptosuccinate inhibits the reaction [lead acetate results in increased expression of CASP3 mRNA]; monoisoamyl-2,3-dimercaptosuccinate inhibits the reaction [sodium arsenite promotes the reaction [lead acetate results in increased expression of CASP3 mRNA]]; Plant Oils inhibits the reaction [lead acetate results in increased expression of CASP3 protein]; Plant Preparations inhibits the reaction [lead acetate results in increased expression of CASP3 mRNA]; Plant Preparations inhibits the reaction [lead acetate results in increased expression of CASP3 protein]; Resveratrol inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of CASP3 protein]; sodium arsenite promotes the reaction [lead acetate results in increased expression of CASP3 mRNA]; sodium bisulfide inhibits the reaction [lead acetate results in increased expression of CASP3 protein]; sodium boranocarbonate inhibits the reaction [lead acetate results in increased expression of CASP3 protein] lead acetate results in increased expression of CASP3 protein; lead acetate results in increased expression of CASP3 protein modified form [S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate results in increased activity of CASP3 protein]; Clotrimazole inhibits the reaction [lead acetate results in increased activity of CASP3 protein]; MIR671 mRNA inhibits the reaction [lead acetate results in increased expression of CASP3 protein]; PPARGC1A protein inhibits the reaction [lead acetate results in increased activity of CASP3 protein]; S-allylcysteine inhibits the reaction [lead acetate results in increased activity of CASP3 protein] lead acetate results in decreased expression of CASP3 mRNA |
CTD |
PMID:19026729 PMID:21640820 PMID:22033380 PMID:23146751 PMID:23318731 PMID:23680456 PMID:23906897 PMID:25031709 PMID:26498409 PMID:26542248 PMID:26797587 PMID:27236077 PMID:27604105 PMID:30251767 PMID:30703413 PMID:30980911 PMID:33242459 PMID:33978298 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
ISO |
1,3-dimethylthiourea inhibits the reaction [lead acetate results in increased activity of CASP8 protein]; [S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate results in increased activity of CASP8 protein]; Clotrimazole inhibits the reaction [lead acetate results in increased activity of CASP8 protein]; Imipramine inhibits the reaction [lead acetate results in increased activity of CASP8 protein]; S-allylcysteine inhibits the reaction [lead acetate results in increased activity of CASP8 protein] |
CTD |
PMID:22033380 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases expression multiple interactions increases activity |
EXP ISO |
lead acetate results in increased expression of CASP9 mRNA lead acetate results in increased expression of CASP9 protein MIR671 mRNA inhibits the reaction [lead acetate results in increased expression of CASP9 protein]; PPARGC1A protein inhibits the reaction [lead acetate results in increased activity of CASP9 protein] [lead acetate results in increased abundance of Lead] which results in increased cleavage of CASP9 protein; [sodium arsenite co-treated with Cadmium Chloride co-treated with lead acetate] results in increased cleavage of CASP9 protein; Carbenoxolone promotes the reaction [[lead acetate results in increased abundance of Lead] which results in increased cleavage of CASP9 protein]; IL1RN protein inhibits the reaction [[sodium arsenite co-treated with Cadmium Chloride co-treated with lead acetate] results in increased cleavage of CASP9 protein]; lead acetate promotes the reaction [sodium arsenite results in increased expression of CASP9 mRNA]; monoisoamyl-2,3-dimercaptosuccinate inhibits the reaction [lead acetate promotes the reaction [sodium arsenite results in increased expression of CASP9 mRNA]]; monoisoamyl-2,3-dimercaptosuccinate inhibits the reaction [lead acetate results in increased expression of CASP9 mRNA]; monoisoamyl-2,3-dimercaptosuccinate inhibits the reaction [sodium arsenite promotes the reaction [lead acetate results in increased expression of CASP9 mRNA]]; SB 203580 inhibits the reaction [[sodium arsenite co-treated with Cadmium Chloride co-treated with lead acetate] results in increased cleavage of CASP9 protein]; sodium arsenite promotes the reaction [lead acetate results in increased expression of CASP9 mRNA] |
CTD |
PMID:23906897 PMID:26396915 PMID:27236077 PMID:27604105 PMID:33242459 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions increases expression affects activity decreases expression decreases activity increases activity |
ISO EXP |
[lead acetate results in increased abundance of Lead] which results in decreased activity of CAT protein; [lead acetate results in increased abundance of Lead] which results in decreased expression of CAT mRNA; [sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of CAT mRNA; Ascorbic Acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased activity of CAT protein]; Ascorbic Acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of CAT mRNA]; rosmarinic acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased activity of CAT protein]; rosmarinic acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of CAT mRNA] lead acetate results in increased expression of CAT mRNA lead acetate results in increased expression of CAT mRNA; lead acetate results in increased expression of CAT protein lead acetate affects the activity of CAT protein lead acetate results in decreased expression of CAT protein lead acetate results in decreased activity of CAT protein [S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate results in decreased activity of CAT protein]; Clotrimazole inhibits the reaction [lead acetate results in decreased activity of CAT protein]; S-allylcysteine inhibits the reaction [lead acetate results in decreased activity of CAT protein] lead acetate results in increased activity of CAT protein 3-nitropropionic acid affects the reaction [[lead acetate results in increased abundance of Lead] affects the reaction [Ethanol affects the expression of CAT protein]]; 3-nitropropionic acid affects the reaction [[lead acetate results in increased abundance of Lead] which affects the expression of CAT protein]; [cadmium acetate co-treated with lead acetate] results in increased activity of CAT protein; [lead acetate co-treated with Cadmium Chloride] results in decreased activity of CAT protein; [lead acetate results in increased abundance of Lead] affects the reaction [Ethanol affects the expression of CAT protein]; [lead acetate results in increased abundance of Lead] which affects the expression of CAT protein; [Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of CAT protein]; Amitrole affects the reaction [[lead acetate results in increased abundance of Lead] affects the reaction [Ethanol affects the expression of CAT protein]]; Amitrole affects the reaction [[lead acetate results in increased abundance of Lead] which affects the expression of CAT protein]; Biological Factors inhibits the reaction [lead acetate results in decreased activity of CAT protein]; Cholecalciferol inhibits the reaction [lead acetate results in decreased activity of CAT protein]; epigallocatechin gallate inhibits the reaction [lead acetate results in decreased activity of CAT protein]; Genistein inhibits the reaction [lead acetate results in decreased expression of CAT protein]; lead acetate promotes the reaction [sodium arsenite results in decreased activity of CAT protein]; lead acetate results in decreased expression of and results in decreased activity of CAT protein; lead acetate results in increased expression of and results in decreased activity of CAT protein; monoisoamyl-2,3-dimercaptosuccinate inhibits the reaction [lead acetate promotes the reaction [sodium arsenite results in decreased activity of CAT protein]]; monoisoamyl-2,3-dimercaptosuccinate inhibits the reaction [lead acetate results in decreased activity of CAT protein]; monoisoamyl-2,3-dimercaptosuccinate inhibits the reaction [sodium arsenite promotes the reaction [lead acetate results in decreased activity of CAT protein]]; Plant Oils inhibits the reaction [lead acetate affects the activity of CAT protein]; Plant Preparations inhibits the reaction [lead acetate results in decreased activity of CAT protein]; sodium arsenite promotes the reaction [lead acetate results in decreased activity of CAT protein] |
CTD |
PMID:12634122 PMID:15569323 PMID:16897041 PMID:19347332 PMID:22033380 PMID:22197700 PMID:22534743 PMID:23906897 PMID:24184865 PMID:24222729 PMID:24970117 PMID:25800560 PMID:26797587 PMID:30251767 PMID:30510688 PMID:30623991 PMID:30703413 PMID:31054310 PMID:31550440 PMID:31610155 PMID:33862172 PMID:34051273 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cav1 |
caveolin 1 |
decreases expression increases expression |
EXP |
lead acetate results in decreased expression of CAV1 mRNA lead acetate results in increased expression of CAV1 mRNA |
CTD |
PMID:11578147 PMID:22641619 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Cbl |
Cbl proto-oncogene |
multiple interactions increases phosphorylation |
EXP |
CBL protein affects the reaction [lead acetate results in decreased expression of PDGFRA protein] lead acetate results in increased phosphorylation of CBL protein |
CTD |
PMID:17298174 |
|
NCBI chr 8:44,487,824...44,571,620
Ensembl chr 8:44,489,410...44,571,176
|
|
G |
Cblb |
Cbl proto-oncogene B |
decreases expression |
ISO |
lead acetate results in decreased expression of CBLB mRNA |
CTD |
PMID:21829687 |
|
NCBI chr11:48,589,878...48,756,940
Ensembl chr11:48,592,703...48,756,839
|
|
G |
Cbx1 |
chromobox 1 |
decreases expression |
ISO |
lead acetate results in decreased expression of CBX1 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr10:81,770,307...81,789,981
Ensembl chr10:81,770,342...81,791,096
|
|
G |
Cbx7 |
chromobox 7 |
increases expression |
ISO |
lead acetate results in increased expression of CBX7 mRNA |
CTD |
PMID:22613225 |
|
NCBI chr 7:111,460,656...111,479,231
Ensembl chr 7:111,460,656...111,477,973
|
|
G |
Ccdc117 |
coiled-coil domain containing 117 |
decreases expression |
ISO |
lead acetate results in decreased expression of CCDC117 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr14:80,399,236...80,409,824
Ensembl chr14:80,400,294...80,409,659
|
|
G |
Ccdc18 |
coiled-coil domain containing 18 |
increases expression |
ISO |
lead acetate results in increased expression of CCDC18 mRNA |
CTD |
PMID:22613225 |
|
NCBI chr14:1,501,749...1,607,672
Ensembl chr14:1,501,784...1,607,711
|
|
G |
Ccdc6 |
coiled-coil domain containing 6 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of CCDC6 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr20:18,432,177...18,528,186
Ensembl chr20:18,433,695...18,528,658
|
|
G |
Ccdc80 |
coiled-coil domain containing 80 |
decreases expression |
ISO |
lead acetate results in decreased expression of CCDC80 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr11:55,685,165...55,718,827
Ensembl chr11:55,685,872...55,719,137
|
|
G |
Cckar |
cholecystokinin A receptor |
decreases expression |
ISO |
lead acetate results in decreased expression of CCKAR mRNA |
CTD |
PMID:22613225 |
|
NCBI chr14:57,292,397...57,300,747
Ensembl chr14:57,292,397...57,300,747
|
|
G |
Ccl1 |
C-C motif chemokine ligand 1 |
increases expression |
ISO |
lead acetate results in increased expression of CCL1 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr10:67,128,331...67,131,109
Ensembl chr10:67,128,331...67,131,159
|
|
G |
Ccl12 |
C-C motif chemokine ligand 12 |
increases expression |
ISO |
lead acetate results in increased expression of CCL12 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr10:67,070,230...67,071,780
Ensembl chr10:67,070,230...67,071,780
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases secretion decreases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lead acetate results in increased secretion of CCL2 protein]; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with U 0126] inhibits the reaction [lead acetate results in increased secretion of CCL2 protein]; Celecoxib inhibits the reaction [lead acetate results in increased secretion of CCL2 protein]; Minocycline inhibits the reaction [lead acetate results in increased secretion of CCL2 protein]; U 0126 inhibits the reaction [lead acetate results in increased secretion of CCL2 protein] lead acetate results in decreased expression of CCL2 mRNA |
CTD |
PMID:21829687 PMID:24530660 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl28 |
C-C motif chemokine ligand 28 |
increases expression |
ISO |
lead acetate results in increased expression of CCL28 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 2:51,601,354...51,625,999
Ensembl chr 2:51,601,331...51,625,997
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
lead acetate promotes the reaction [Hemagglutinins results in increased secretion of CCL3 protein] |
CTD |
PMID:22839698 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
ISO |
lead acetate results in increased expression of CCL5 mRNA |
CTD |
PMID:29746905 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccn1 |
cellular communication network factor 1 |
affects expression |
EXP |
lead acetate affects the expression of CCN1 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression |
ISO |
lead acetate results in decreased expression of CCN2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions increases expression decreases expression |
ISO EXP |
APEX1 protein promotes the reaction [lead acetate results in increased expression of CCND1 protein]; E 3330 inhibits the reaction [lead acetate results in increased expression of CCND1 protein] lead acetate results in increased expression of CCND1 mRNA lead acetate results in decreased expression of CCND1 mRNA |
CTD |
PMID:23370007 PMID:25270620 PMID:33862172 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
lead acetate results in decreased expression of CCNE1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
increases expression |
EXP ISO |
lead acetate results in increased expression of CCR2 mRNA |
CTD |
PMID:22609695 PMID:22641619 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Ccr4 |
C-C motif chemokine receptor 4 |
increases expression |
ISO |
lead acetate results in increased expression of CCR4 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 8:114,176,256...114,182,155
Ensembl chr 8:114,176,974...114,178,056
|
|
G |
Ccr7 |
C-C motif chemokine receptor 7 |
decreases expression |
ISO |
lead acetate results in decreased expression of CCR7 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309
|
|
G |
Ccr8 |
C-C motif chemokine receptor 8 |
increases expression |
ISO |
lead acetate results in increased expression of CCR8 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 8:119,826,332...119,828,292
Ensembl chr 8:119,826,568...119,827,629
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
increases expression |
ISO |
lead acetate results in increased expression of CCS mRNA |
CTD |
PMID:29746905 |
|
NCBI chr 1:202,113,792...202,134,931
Ensembl chr 1:202,113,804...202,134,915
|
|
G |
Cd163 |
CD163 molecule |
increases expression |
EXP |
lead acetate results in increased expression of CD163 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 4:157,085,080...157,118,470
Ensembl chr 4:157,085,093...157,117,878
|
|
G |
Cd247 |
Cd247 molecule |
increases expression |
ISO |
lead acetate results in increased expression of CD247 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr13:78,043,302...78,118,437
Ensembl chr13:78,043,307...78,122,263
|
|
G |
Cd27 |
CD27 molecule |
increases expression decreases expression |
ISO |
lead acetate results in increased expression of CD27 mRNA lead acetate results in decreased expression of CD27 mRNA |
CTD |
PMID:20542052 PMID:21829687 |
|
NCBI chr 4:158,030,700...158,035,862
Ensembl chr 4:158,030,703...158,035,592
|
|
G |
Cd300c2 |
CD300C molecule 2 |
increases expression |
ISO |
lead acetate results in increased expression of CD300C2 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr10:100,253,312...100,258,553
Ensembl chr10:100,253,624...100,258,323
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
lead acetate results in increased expression of CD36 mRNA |
CTD |
PMID:30623991 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd3e |
CD3 epsilon subunit of T-cell receptor complex |
increases expression increases methylation |
EXP |
lead acetate results in increased expression of CD3E mRNA lead acetate results in increased methylation of CD3E gene |
CTD |
PMID:22641619 PMID:29571894 |
|
NCBI chr 8:45,303,848...45,315,297
Ensembl chr 8:45,303,852...45,315,022
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with lead acetate co-treated with CSF2 protein] results in increased expression of CD40 protein |
CTD |
PMID:17512567 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd47 |
Cd47 molecule |
decreases expression |
ISO |
lead acetate results in decreased expression of CD47 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr11:50,906,052...50,970,000
Ensembl chr11:50,906,177...50,969,425
|
|
G |
Cd48 |
Cd48 molecule |
increases expression |
EXP |
lead acetate results in increased expression of CD48 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr13:84,184,884...84,209,144
Ensembl chr13:84,185,532...84,209,142
|
|
G |
Cd59 |
CD59 molecule |
increases mutagenesis |
ISO |
lead acetate results in increased mutagenesis of CD59 protein |
CTD |
PMID:17045307 |
|
NCBI chr 3:90,459,085...90,477,571
Ensembl chr 3:90,459,162...90,478,847
|
|
G |
Cd68 |
Cd68 molecule |
increases expression |
ISO |
lead acetate results in increased expression of CD68 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cd79a |
CD79a molecule |
decreases expression |
ISO |
lead acetate results in decreased expression of CD79A mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 1:80,493,520...80,497,936
Ensembl chr 1:80,493,581...80,497,935
|
|
G |
Cd80 |
Cd80 molecule |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with lead acetate co-treated with CSF2 protein] results in increased expression of CD80 protein |
CTD |
PMID:17512567 |
|
NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with lead acetate co-treated with CSF2 protein] results in increased expression of CD86 protein |
CTD |
PMID:17512567 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cd93 |
CD93 molecule |
decreases expression |
EXP ISO |
lead acetate results in decreased expression of CD93 mRNA |
CTD |
PMID:22613225 PMID:22641619 |
|
NCBI chr 3:135,891,859...135,898,378
Ensembl chr 3:135,891,859...135,898,378
|
|
G |
Cd99 |
CD99 molecule (Xg blood group) |
decreases expression |
ISO |
lead acetate results in decreased expression of CD99 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr20:54,418,239...54,422,882
|
|
G |
Cdc42ep5 |
CDC42 effector protein 5 |
decreases expression |
EXP |
lead acetate results in decreased expression of CDC42EP5 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 1:70,035,921...70,038,990
|
|
G |
Cdc45 |
cell division cycle 45 |
increases expression |
ISO |
lead acetate results in increased expression of CDC45 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619
|
|
G |
Cdc6 |
cell division cycle 6 |
decreases expression |
ISO |
lead acetate results in decreased expression of CDC6 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011
|
|
G |
Cdca8 |
cell division cycle associated 8 |
increases expression |
ISO |
lead acetate results in increased expression of CDCA8 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 5:137,176,414...137,198,686
Ensembl chr 5:137,176,417...137,198,629
|
|
G |
Cdh11 |
cadherin 11 |
decreases expression |
EXP |
lead acetate results in decreased expression of CDH11 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr19:2,148,447...2,305,754
Ensembl chr19:2,148,458...2,304,272
|
|
G |
Cdh17 |
cadherin 17 |
increases expression |
ISO |
lead acetate results in increased expression of CDH17 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 5:25,262,820...25,314,884
Ensembl chr 5:25,262,758...25,314,884
|
|
G |
Cdh19 |
cadherin 19 |
decreases expression |
EXP |
lead acetate results in decreased expression of CDH19 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr13:27,935,915...28,047,490
Ensembl chr13:27,936,668...28,019,310
|
|
G |
Cdh3 |
cadherin 3 |
affects expression |
EXP |
lead acetate affects the expression of CDH3 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr19:34,393,596...34,444,084
Ensembl chr19:34,393,727...34,444,084
|
|
G |
Cdh7 |
cadherin 7 |
decreases expression |
EXP |
lead acetate results in decreased expression of CDH7 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr13:26,672,058...26,821,571
Ensembl chr13:26,672,484...26,819,846
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
increases methylation decreases expression |
EXP |
lead acetate results in increased methylation of CDK1 gene lead acetate results in decreased expression of CDK1 mRNA |
CTD |
PMID:29571894 PMID:33862172 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk13 |
cyclin-dependent kinase 13 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of CDK13 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr17:47,251,145...47,344,675
Ensembl chr17:47,251,163...47,341,721
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
multiple interactions increases expression increases cleavage |
EXP ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[sodium arsenite co-treated with lead acetate co-treated with Cadmium Chloride] results in increased phosphorylation of CDK5 protein]; [sodium arsenite co-treated with lead acetate co-treated with Cadmium Chloride] promotes the reaction [CDK5 protein results in increased phosphorylation of PPARG protein]; [sodium arsenite co-treated with lead acetate co-treated with Cadmium Chloride] results in increased phosphorylation of and results in increased activity of CDK5 protein; pyrazolanthrone inhibits the reaction [[sodium arsenite co-treated with lead acetate co-treated with Cadmium Chloride] results in increased phosphorylation of CDK5 protein] lead acetate results in increased expression of CDK5 mRNA; lead acetate results in increased expression of CDK5 protein lead acetate results in increased cleavage of CDK5 protein |
CTD |
PMID:24481447 PMID:24954411 PMID:27012722 PMID:27293183 |
|
NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112
|
|
G |
Cdk5r1 |
cyclin-dependent kinase 5 regulatory subunit 1 |
multiple interactions |
ISO |
lead acetate affects the reaction [MAPT protein affects the abundance of CDK5R1 protein modified form]; lead acetate results in decreased expression of and results in increased cleavage of CDK5R1 protein |
CTD |
PMID:24954411 PMID:29203278 |
|
NCBI chr10:65,484,266...65,485,467
Ensembl chr10:65,483,941...65,488,456
|
|
G |
Cdkal1 |
CDK5 regulatory subunit associated protein 1-like 1 |
increases expression |
ISO |
lead acetate results in increased expression of CDKAL1 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr17:34,718,680...34,769,614 NCBI chr17:34,852,238...35,271,276
Ensembl chr17:34,718,687...35,407,524
|
|
G |
Cdkl4 |
cyclin-dependent kinase-like 4 |
increases expression |
EXP |
lead acetate results in increased expression of CDKL4 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 6:14,449,822...14,492,568
Ensembl chr 6:14,450,681...14,492,046
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO EXP |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of CDKN1A mRNA [lead acetate results in increased abundance of Lead] which results in decreased expression of CDKN1A protein lead acetate results in increased expression of CDKN1A mRNA |
CTD |
PMID:12634122 PMID:22641619 PMID:34350654 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
ISO |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in increased expression of CDKN2A mRNA |
CTD |
PMID:12634122 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
increases expression |
EXP |
lead acetate results in increased expression of CDKN2B mRNA |
CTD |
PMID:33862172 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
decreases expression |
EXP |
lead acetate results in decreased expression of CDKN2C mRNA |
CTD |
PMID:33862172 |
|
NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
increases expression |
EXP |
lead acetate results in increased expression of CDKN3 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Cdon |
cell adhesion associated, oncogene regulated |
increases expression |
ISO |
lead acetate results in increased expression of CDON mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 8:33,775,123...33,861,635
Ensembl chr 8:33,806,183...33,859,033
|
|
G |
Cdr2 |
cerebellar degeneration-related protein 2 |
affects expression |
EXP |
lead acetate affects the expression of CDR2 mRNA |
CTD |
PMID:21864555 |
|
NCBI chr 1:175,502,837...175,527,746
Ensembl chr 1:175,502,838...175,537,472
|
|
G |
Cds2 |
CDP-diacylglycerol synthase 2 |
increases expression |
ISO |
lead acetate results in increased expression of CDS2 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 3:119,514,963...119,553,555
Ensembl chr 3:119,515,000...119,553,541
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
decreases expression increases methylation increases expression |
EXP ISO |
lead acetate results in decreased expression of CEACAM1 mRNA lead acetate results in increased methylation of CEACAM1 gene lead acetate results in increased expression of CEACAM1 mRNA |
CTD |
PMID:22609695 PMID:22641619 PMID:29571894 |
|
NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992
|
|
G |
Ceacam4 |
CEA cell adhesion molecule 4 |
increases expression affects methylation |
EXP |
lead acetate results in increased expression of CEACAM10 mRNA lead acetate affects the methylation of CEACAM3 gene |
CTD |
PMID:22641619 PMID:29571894 |
|
NCBI chr 1:80,376,667...80,382,943
Ensembl chr 1:80,376,648...80,382,915
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
increases expression increases methylation decreases expression |
ISO EXP |
lead acetate results in increased expression of CEBPA mRNA lead acetate results in increased methylation of CEBPA gene lead acetate results in decreased expression of CEBPA mRNA |
CTD |
PMID:20542052 PMID:21829687 PMID:29571894 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
affects expression increases expression |
ISO |
lead acetate affects the expression of CEBPB mRNA lead acetate results in increased expression of CEBPB mRNA |
CTD |
PMID:21829687 PMID:25270620 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cebpe |
CCAAT/enhancer binding protein epsilon |
increases methylation |
EXP |
lead acetate results in increased methylation of CEBPE gene |
CTD |
PMID:29571894 |
|
NCBI chr15:28,169,885...28,171,283
Ensembl chr15:28,169,704...28,171,814
|
|
G |
Cel |
carboxyl ester lipase |
increases expression |
ISO |
lead acetate results in increased expression of CEL mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035
|
|
G |
Cela3b |
chymotrypsin like elastase 3B |
increases expression |
ISO |
lead acetate results in increased expression of CELA3B mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 5:149,628,773...149,636,937
Ensembl chr 5:149,628,773...149,636,937
|
|
G |
Cemip2 |
cell migration inducing hyaluronidase 2 |
decreases expression |
ISO |
lead acetate results in decreased expression of CEMIP2 mRNA |
CTD |
PMID:22613225 |
|
NCBI chr 1:219,330,295...219,407,760
Ensembl chr 1:219,337,985...219,407,760
|
|
G |
Cend1 |
cell cycle exit and neuronal differentiation 1 |
increases expression |
ISO |
lead acetate results in increased expression of CEND1 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 1:196,525,153...196,528,152
Ensembl chr 1:196,523,920...196,528,302
|
|
G |
Cenpe |
centromere protein E |
increases expression |
EXP |
lead acetate results in increased expression of CENPE mRNA |
CTD |
PMID:11578147 |
|
NCBI chr 2:223,637,035...223,695,692
Ensembl chr 2:223,636,998...223,695,669
|
|
G |
Cenpk |
centromere protein K |
increases expression |
EXP |
lead acetate results in increased expression of CENPK mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 2:35,360,132...35,421,372
Ensembl chr 2:35,360,132...35,385,706
|
|
G |
Cenpo |
centromere protein O |
decreases expression |
ISO |
lead acetate results in decreased expression of CENPO mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 6:27,203,642...27,218,394
Ensembl chr 6:27,188,537...27,218,314
|
|
G |
Cenpv |
centromere protein V |
decreases expression |
ISO |
lead acetate results in decreased expression of CENPV mRNA |
CTD |
PMID:20542052 |
|
NCBI chr10:47,214,479...47,228,552
Ensembl chr10:47,214,490...47,228,761
|
|
G |
Cep162 |
centrosomal protein 162 |
increases expression |
EXP |
lead acetate results in increased expression of CEP162 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 8:88,149,726...88,208,249
Ensembl chr 8:88,149,726...88,206,830
|
|
G |
Cept1 |
choline/ethanolamine phosphotransferase 1 |
decreases expression |
ISO |
lead acetate results in decreased expression of CEPT1 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 2:193,994,220...194,036,141
Ensembl chr 2:193,993,447...194,035,578
|
|
G |
Cers4 |
ceramide synthase 4 |
decreases expression |
ISO |
lead acetate results in decreased expression of CERS4 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr12:2,851,784...2,890,244
Ensembl chr12:2,851,784...2,886,828
|
|
G |
Cfap126 |
cilia and flagella associated protein 126 |
affects expression |
EXP |
lead acetate affects the expression of CFAP126 mRNA |
CTD |
PMID:21864555 |
|
NCBI chr13:83,526,657...83,542,552
Ensembl chr13:83,526,657...83,542,552
|
|
G |
Cfap70 |
cilia and flagella associated protein 70 |
increases expression |
EXP |
lead acetate results in increased expression of CFAP70 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr15:3,852,381...3,918,036
Ensembl chr15:3,852,509...3,918,014
|
|
G |
Cfap77 |
cilia and flagella associated protein 77 |
decreases expression |
EXP |
lead acetate results in decreased expression of CFAP77 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 3:12,258,453...12,381,319
Ensembl chr 3:12,258,453...12,381,319
|
|
G |
Cfhr1 |
complement factor H-related 1 |
decreases expression |
ISO |
lead acetate results in decreased expression of CFHR1 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr13:51,395,583...51,410,571
Ensembl chr13:51,369,211...51,410,592
|
|
G |
Cfp |
complement factor properdin |
increases expression |
ISO |
lead acetate results in increased expression of CFP mRNA |
CTD |
PMID:20542052 |
|
NCBI chr X:1,162,014...1,167,576
Ensembl chr X:1,161,979...1,167,573
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
decreases activity multiple interactions |
ISO |
lead acetate results in decreased activity of CGA protein lead acetate inhibits the reaction [CGA protein results in increased abundance of Progesterone] |
CTD |
PMID:11213355 PMID:12647776 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Cgref1 |
cell growth regulator with EF hand domain 1 |
decreases expression affects methylation |
EXP |
lead acetate results in decreased expression of CGREF1 mRNA lead acetate affects the methylation of CGREF1 gene |
CTD |
PMID:29571894 |
|
NCBI chr 6:25,431,846...25,443,853
Ensembl chr 6:25,431,799...25,443,852
|
|
G |
Chchd5 |
coiled-coil-helix-coiled-coil-helix domain containing 5 |
increases expression |
EXP |
lead acetate results in increased expression of CHCHD5 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 3:116,361,845...116,372,238
Ensembl chr 3:116,361,885...116,367,169
|
|
G |
Chd3 |
chromodomain helicase DNA binding protein 3 |
decreases expression |
ISO |
lead acetate results in decreased expression of CHD3 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr10:54,063,629...54,090,030
Ensembl chr10:54,063,629...54,090,047
|
|
G |
Chd7 |
chromodomain helicase DNA binding protein 7 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of CHD7 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 5:21,812,007...21,995,358
Ensembl chr 5:21,812,070...21,995,358
|
|
G |
Chdh |
choline dehydrogenase |
increases expression |
ISO |
lead acetate results in increased expression of CHDH mRNA |
CTD |
PMID:22613225 |
|
NCBI chr16:5,194,269...5,225,541
Ensembl chr16:5,194,269...5,225,537
|
|
G |
Chek1 |
checkpoint kinase 1 |
increases expression |
ISO EXP |
lead acetate results in increased expression of CHEK1 mRNA |
CTD |
PMID:22609695 PMID:33862172 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chid1 |
chitinase domain containing 1 |
increases expression |
ISO |
lead acetate results in increased expression of CHID1 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 1:196,594,357...196,629,700
Ensembl chr 1:196,587,509...196,629,606
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
decreases expression increases expression |
EXP |
lead acetate results in decreased expression of CHRNA7 mRNA lead acetate results in increased expression of CHRNA7 mRNA |
CTD |
PMID:33862172 |
|
NCBI chr 1:116,715,286...116,837,223
Ensembl chr 1:116,714,711...116,837,240
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
increases expression |
EXP |
lead acetate results in increased expression of CHRNB2 mRNA |
CTD |
PMID:33862172 |
|
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
decreases expression |
EXP |
lead acetate results in decreased expression of CHRNB4 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 8:55,418,379...55,436,967
Ensembl chr 8:55,418,313...55,437,027
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
decreases expression |
EXP |
lead acetate results in decreased expression of CHUK protein |
CTD |
PMID:16547843 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Ciapin1 |
cytokine induced apoptosis inhibitor 1 |
increases expression |
ISO |
lead acetate results in increased expression of CIAPIN1 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr19:10,179,963...10,195,511
Ensembl chr19:10,180,100...10,195,503
|
|
G |
Ckb |
creatine kinase B |
multiple interactions increases expression |
ISO EXP |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of CKB mRNA Curcumin inhibits the reaction [lead acetate results in increased secretion of [CKM protein binds to CKB protein]]; lead acetate results in increased secretion of [CKM protein binds to CKB protein] lead acetate results in increased expression of CKB protein |
CTD |
PMID:12634122 PMID:20797405 PMID:21378372 |
|
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
|
|
G |
Cklf |
chemokine-like factor |
affects expression |
ISO |
lead acetate affects the expression of CKLF mRNA |
CTD |
PMID:21829687 |
|
NCBI chr19:698,097...706,570
Ensembl chr19:698,033...706,570
|
|
G |
Ckm |
creatine kinase, M-type |
multiple interactions increases expression |
ISO EXP |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of CKM mRNA Curcumin inhibits the reaction [lead acetate results in increased secretion of [CKM protein binds to CKB protein]]; lead acetate results in increased secretion of [CKM protein binds to CKB protein] lead acetate results in increased expression of CKM mRNA |
CTD |
PMID:11578147 PMID:12634122 PMID:21378372 |
|
NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720
|
|
G |
Clcn3 |
chloride voltage-gated channel 3 |
increases expression |
EXP |
lead acetate results in increased expression of CLCN3 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr16:29,127,419...29,200,133
Ensembl chr16:29,127,419...29,200,119
|
|
G |
Clcn7 |
chloride voltage-gated channel 7 |
increases expression |
EXP |
lead acetate results in increased expression of CLCN7 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr10:14,151,758...14,177,130
Ensembl chr10:14,151,758...14,177,130
|
|
G |
Cldn1 |
claudin 1 |
affects expression |
EXP |
lead acetate affects the expression of CLDN1 mRNA |
CTD |
PMID:21864555 |
|
NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Cldn19 |
claudin 19 |
affects expression |
EXP |
lead acetate affects the expression of CLDN19 mRNA |
CTD |
PMID:21864555 |
|
NCBI chr 5:132,862,939...132,870,364
Ensembl chr 5:132,863,267...132,868,227
|
|
G |
Cldn23 |
claudin 23 |
increases expression |
ISO |
lead acetate results in increased expression of CLDN23 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr16:56,413,677...56,415,401
Ensembl chr16:56,413,381...56,415,523
|
|
G |
Cldn5 |
claudin 5 |
multiple interactions decreases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lead acetate results in decreased expression of CLDN5 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lead acetate results in decreased expression of CLDN5 protein] [lead acetate results in increased abundance of Lead] which results in decreased expression of CLDN5 protein |
CTD |
PMID:24200059 PMID:31730887 |
|
NCBI chr11:82,212,822...82,214,248
Ensembl chr11:82,211,475...82,214,992
|
|
G |
Clec3a |
C-type lectin domain family 3, member A |
increases expression |
EXP |
lead acetate results in increased expression of CLEC3A mRNA |
CTD |
PMID:22641619 |
|
NCBI chr19:42,404,628...42,412,008
Ensembl chr19:42,404,628...42,412,008
|
|
G |
Clec4a |
C-type lectin domain family 4, member A |
increases expression |
ISO |
lead acetate results in increased expression of CLEC4N mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 4:156,340,439...156,434,212
Ensembl chr 4:156,414,688...156,432,402
|
|
G |
Clgn |
calmegin |
decreases expression |
ISO |
lead acetate results in decreased expression of CLGN mRNA |
CTD |
PMID:22609695 |
|
NCBI chr19:24,695,140...24,728,542
Ensembl chr19:24,696,875...24,728,758
|
|
G |
Clic6 |
chloride intracellular channel 6 |
affects expression |
EXP |
lead acetate affects the expression of CLIC6 mRNA |
CTD |
PMID:21864555 |
|
NCBI chr11:31,737,813...31,780,360
Ensembl chr11:31,737,813...31,780,061
|
|
G |
Cltrn |
collectrin, amino acid transport regulator |
affects expression |
EXP |
lead acetate affects the expression of CLTRN mRNA |
CTD |
PMID:22641619 |
|
NCBI chr X:30,361,967...30,395,264
Ensembl chr X:30,361,967...30,395,349
|
|
G |
Clxn |
calaxin |
affects expression decreases expression |
EXP |
lead acetate affects the expression of CLXN mRNA lead acetate results in decreased expression of CLXN mRNA |
CTD |
PMID:21864555 PMID:22641619 |
|
NCBI chr11:85,977,231...85,996,561
Ensembl chr11:85,983,304...85,996,538
|
|
G |
Cmbl |
carboxymethylenebutenolidase homolog |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of CMBL mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 2:82,569,257...82,591,007
Ensembl chr 2:82,571,888...82,591,009
|
|
G |
Cmc1 |
C-x(9)-C motif containing 1 |
decreases expression |
ISO |
lead acetate results in decreased expression of CMC1 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 8:117,798,036...117,900,458
Ensembl chr 8:117,798,945...117,900,462
|
|
G |
Cndp2 |
carnosine dipeptidase 2 |
increases expression |
ISO |
lead acetate results in increased expression of CNDP2 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr18:78,039,924...78,057,030
Ensembl chr18:78,039,932...78,056,922
|
|
G |
Cngb3 |
cyclic nucleotide gated channel subunit beta 3 |
decreases expression |
EXP |
lead acetate results in decreased expression of CNGB3 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 5:32,746,988...32,995,121
Ensembl chr 5:32,746,988...32,995,121
|
|
G |
Cnmd |
chondromodulin |
affects expression |
EXP |
lead acetate affects the expression of CNMD mRNA |
CTD |
PMID:22641619 |
|
NCBI chr15:55,041,548...55,066,297
Ensembl chr15:55,041,561...55,066,297
|
|
G |
Cnnm3 |
cyclin and CBS domain divalent metal cation transport mediator 3 |
decreases expression |
ISO |
lead acetate results in decreased expression of CNNM3 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 9:38,755,374...38,770,740
Ensembl chr 9:38,755,390...38,770,740
|
|
G |
Cnp |
2',3'-cyclic nucleotide 3' phosphodiesterase |
decreases expression multiple interactions |
ISO EXP |
lead acetate results in decreased expression of CNP protein [sodium arsenite co-treated with lead acetate co-treated with Cadmium Chloride] results in decreased expression of CNP protein |
CTD |
PMID:20797405 PMID:23680456 |
|
NCBI chr10:85,511,164...85,517,723
Ensembl chr10:85,511,160...85,517,720
|
|
G |
Cntf |
ciliary neurotrophic factor |
decreases expression |
EXP |
lead acetate results in decreased expression of CNTF mRNA |
CTD |
PMID:33862172 |
|
NCBI chr 1:209,887,854...209,889,877
Ensembl chr 1:209,887,854...209,889,877
|
|
G |
Cntnap2 |
contactin associated protein 2 |
decreases expression |
ISO |
lead acetate results in decreased expression of CNTNAP2 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 4:74,109,455...76,366,434
Ensembl chr 4:74,109,472...76,362,027
|
|
G |
Cog8 |
component of oligomeric golgi complex 8 |
decreases expression |
ISO |
lead acetate results in decreased expression of COG8 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr19:34,951,625...34,962,377
Ensembl chr19:34,951,627...34,962,397
|
|
G |
Col11a1 |
collagen type XI alpha 1 chain |
decreases expression |
EXP |
lead acetate results in decreased expression of COL11A1 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853
|
|
G |
Col13a1 |
collagen type XIII alpha 1 chain |
decreases expression |
EXP |
lead acetate results in decreased expression of COL13A1 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr20:29,783,965...29,924,116
Ensembl chr20:29,783,965...29,924,032
|
|
G |
Col15a1 |
collagen type XV alpha 1 chain |
decreases expression |
EXP ISO |
lead acetate results in decreased expression of COL15A1 mRNA |
CTD |
PMID:11578147 PMID:22613225 |
|
NCBI chr 5:61,501,963...61,607,591
Ensembl chr 5:61,501,963...61,607,591
|
|
G |
Col16a1 |
collagen type XVI alpha 1 chain |
decreases expression |
EXP |
lead acetate results in decreased expression of COL16A1 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr 5:142,388,376...142,442,825
Ensembl chr 5:142,388,426...142,442,825
|
|
G |
Col18a1 |
collagen type XVIII alpha 1 chain |
decreases expression |
EXP |
lead acetate results in decreased expression of COL18A1 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,474,104...11,582,593
|
|
G |
Col19a1 |
collagen type XIX alpha 1 chain |
decreases expression increases expression |
EXP ISO |
lead acetate results in decreased expression of COL19A1 mRNA lead acetate results in increased expression of COL19A1 mRNA |
CTD |
PMID:11578147 PMID:20542052 |
|
NCBI chr 9:26,673,916...27,022,139
Ensembl chr 9:26,675,391...27,022,106
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression increases expression |
EXP |
lead acetate results in decreased expression of COL1A1 mRNA lead acetate results in increased expression of COL1A1 mRNA |
CTD |
PMID:11578147 PMID:22641619 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col22a1 |
collagen type XXII alpha 1 chain |
decreases expression |
ISO |
lead acetate results in decreased expression of COL22A1 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 7:103,730,939...103,968,452
Ensembl chr 7:103,731,037...103,968,462
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions increases expression decreases expression |
ISO EXP |
BMP2 promotes the reaction [lead acetate results in increased expression of COL2A1 mRNA] lead acetate results in decreased expression of COL2A1 mRNA |
CTD |
PMID:11578147 PMID:17805416 |
|
NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
decreases expression |
EXP |
lead acetate results in decreased expression of COL4A1 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412
|
|
G |
Col4a3 |
collagen type IV alpha 3 chain |
increases expression |
EXP |
lead acetate results in increased expression of COL4A3 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr 9:83,875,958...84,004,955
Ensembl chr 9:83,875,561...84,001,895
|
|
G |
Col4a4 |
collagen type IV alpha 4 chain |
decreases expression |
EXP |
lead acetate results in decreased expression of COL4A4 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr 9:83,833,173...83,875,436
Ensembl chr 9:83,755,515...83,875,876
|
|
G |
Col4a5 |
collagen type IV alpha 5 chain |
decreases expression |
EXP |
lead acetate results in decreased expression of COL4A5 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr X:105,118,762...105,322,699
Ensembl chr X:105,118,820...105,322,692
|
|
G |
Col4a6 |
collagen type IV alpha 6 chain |
decreases expression |
EXP |
lead acetate results in decreased expression of COL4A6 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr X:104,766,463...105,117,499
Ensembl chr X:104,766,957...105,117,500
|
|
G |
Col5a2 |
collagen type V alpha 2 chain |
decreases expression |
EXP |
lead acetate results in decreased expression of COL5A2 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr 9:47,448,736...47,598,396
Ensembl chr 9:47,448,736...47,598,154
|
|
G |
Col6a1 |
collagen type VI alpha 1 chain |
increases expression |
EXP |
lead acetate results in increased expression of COL6A1 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr20:11,906,105...11,924,599
Ensembl chr20:11,905,957...11,924,597
|
|
G |
Col6a2 |
collagen type VI alpha 2 chain |
multiple interactions |
ISO |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in increased expression of COL6A2 mRNA |
CTD |
PMID:12634122 |
|
NCBI chr20:12,021,676...12,049,425
Ensembl chr20:12,021,767...12,057,564
|
|
G |
Col7a1 |
collagen type VII alpha 1 chain |
increases expression |
EXP |
lead acetate results in increased expression of COL7A1 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr 8:109,604,877...109,637,252
Ensembl chr 8:109,604,861...109,637,252
|
|
G |
Col8a1 |
collagen type VIII alpha 1 chain |
decreases expression |
EXP |
lead acetate results in decreased expression of COL8A1 mRNA |
CTD |
PMID:11578147 PMID:22641619 |
|
NCBI chr11:42,776,851...42,906,432
Ensembl chr11:42,777,628...42,906,424
|
|
G |
Col9a1 |
collagen type IX alpha 1 chain |
decreases expression |
EXP |
lead acetate results in decreased expression of COL9A1 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr 9:26,585,034...26,668,222
Ensembl chr 9:26,585,034...26,668,213
|
|
G |
Col9a3 |
collagen type IX alpha 3 chain |
decreases expression |
EXP |
lead acetate results in decreased expression of COL9A3 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr 3:167,711,776...167,734,468
Ensembl chr 3:167,711,840...167,734,465
|
|
G |
Colgalt1 |
collagen beta(1-O)galactosyltransferase 1 |
increases expression |
ISO |
lead acetate results in increased expression of COLGALT1 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr16:18,319,796...18,332,106
Ensembl chr16:18,319,795...18,332,106
|
|
G |
Commd6 |
COMM domain containing 6 |
increases expression |
EXP |
lead acetate results in increased expression of COMMD6 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr15:78,467,333...78,474,382
Ensembl chr15:78,467,804...78,474,382
|
|
G |
Coprs |
coordinator of PRMT5 and differentiation stimulator |
increases expression |
ISO |
lead acetate results in increased expression of COPRS mRNA |
CTD |
PMID:22609695 |
|
NCBI chr16:75,721,264...75,726,375
Ensembl chr16:75,720,061...75,726,375
|
|
G |
Cp |
ceruloplasmin |
multiple interactions decreases expression |
EXP |
[Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of CP protein] |
CTD |
PMID:22534743 |
|
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Cpa1 |
carboxypeptidase A1 |
increases expression |
ISO |
lead acetate results in increased expression of CPA1 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 4:59,257,417...59,263,544
Ensembl chr 4:59,257,417...59,263,544
|
|
G |
Cpa2 |
carboxypeptidase A2 |
increases expression |
ISO |
lead acetate results in increased expression of CPA2 mRNA |
CTD |
PMID:20542052 PMID:22609695 |
|
NCBI chr 4:59,160,357...59,183,677
Ensembl chr 4:59,160,357...59,183,674
|
|
G |
Cpa5 |
carboxypeptidase A5 |
increases expression |
ISO |
lead acetate results in increased expression of CPA5 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 4:59,229,754...59,249,503
Ensembl chr 4:59,230,964...59,249,490
|
|
G |
Cpb1 |
carboxypeptidase B1 |
increases expression |
ISO |
lead acetate results in increased expression of CPB1 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 2:102,755,241...102,785,628
Ensembl chr 2:102,755,241...102,785,628
|
|
G |
Cpb2 |
carboxypeptidase B2 |
increases expression |
ISO |
lead acetate results in increased expression of CPB2 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr15:50,557,722...50,606,569
Ensembl chr15:50,557,717...50,606,556
|
|
G |
Cplx4 |
complexin 4 |
decreases expression |
EXP |
lead acetate results in decreased expression of CPLX4 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr18:59,481,360...59,504,716
Ensembl chr18:59,481,986...59,497,778
|
|
G |
Cpne1 |
copine 1 |
increases expression |
ISO |
lead acetate results in increased expression of CPNE1 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 3:144,587,548...144,629,603
Ensembl chr 3:144,588,995...144,598,636
|
|
G |
Cpsf3 |
cleavage and polyadenylation specific factor 3 |
decreases expression |
ISO |
lead acetate results in decreased expression of CPSF3 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 6:40,836,121...40,864,129
Ensembl chr 6:40,836,097...40,864,128
|
|
G |
Crabp1 |
cellular retinoic acid binding protein 1 |
decreases expression decreases methylation increases expression |
EXP |
lead acetate results in decreased expression of CRABP1 mRNA lead acetate results in decreased methylation of CRABP1 gene lead acetate results in increased expression of CRABP1 mRNA |
CTD |
PMID:22641619 PMID:29571894 |
|
NCBI chr 8:55,138,363...55,159,360
Ensembl chr 8:55,151,285...55,159,360
|
|
G |
Crb3 |
crumbs cell polarity complex component 3 |
decreases expression increases expression |
EXP ISO |
lead acetate results in decreased expression of CRB3 mRNA lead acetate results in increased expression of CRB3 mRNA |
CTD |
PMID:22609695 PMID:22641619 |
|
NCBI chr 9:1,898,531...1,903,860
Ensembl chr 9:1,896,623...1,903,859
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions decreases phosphorylation decreases expression |
EXP ISO |
[lead acetate promotes the reaction [GRIN1 protein binds to GRIN2B protein]] which results in decreased phosphorylation of CREB1 protein; [lead acetate results in increased abundance of Lead] which results in decreased expression of CREB1 mRNA; [lead acetate results in increased abundance of Lead] which results in decreased phosphorylation of CREB1 protein; Resveratrol inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of CREB1 mRNA]; Resveratrol inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased phosphorylation of CREB1 protein] Quercetin inhibits the reaction [lead acetate results in decreased phosphorylation of CREB1 protein] lead acetate results in decreased expression of CREB1 mRNA |
CTD |
PMID:12480136 PMID:23855546 PMID:24260418 PMID:30905827 PMID:33978298 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Creb3l3 |
cAMP responsive element binding protein 3-like 3 |
decreases expression |
ISO |
lead acetate results in decreased expression of CREB3L3 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 7:8,622,614...8,631,053
Ensembl chr 7:8,622,614...8,631,048
|
|
G |
Creb5 |
cAMP responsive element binding protein 5 |
increases expression |
ISO |
lead acetate results in increased expression of CREB5 mRNA |
CTD |
PMID:24260418 |
|
NCBI chr 4:82,393,091...82,794,320
Ensembl chr 4:82,393,730...82,790,325
|
|
G |
Crhr2 |
corticotropin releasing hormone receptor 2 |
increases expression |
ISO |
lead acetate results in increased expression of CRHR2 mRNA |
CTD |
PMID:22613225 |
|
NCBI chr 4:84,222,897...84,265,924
Ensembl chr 4:84,224,002...84,265,904
|
|
G |
Crispld1 |
cysteine-rich secretory protein LCCL domain containing 1 |
increases expression |
EXP |
lead acetate results in increased expression of CRISPLD1 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 5:1,267,347...1,314,926
Ensembl chr 5:1,274,647...1,314,926
|
|
G |
Crispld2 |
cysteine-rich secretory protein LCCL domain containing 2 |
affects expression |
ISO |
lead acetate affects the expression of CRISPLD2 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr19:48,053,153...48,111,485
Ensembl chr19:48,053,287...48,110,465
|
|
G |
Crkl |
CRK like proto-oncogene, adaptor protein |
decreases expression |
ISO |
lead acetate results in decreased expression of CRKL mRNA |
CTD |
PMID:22609695 |
|
NCBI chr11:83,528,788...83,563,214
Ensembl chr11:83,526,530...83,563,238
|
|
G |
Crnkl1 |
crooked neck pre-mRNA splicing factor 1 |
decreases expression |
ISO |
lead acetate results in decreased expression of CRNKL1 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 3:133,338,593...133,354,329
Ensembl chr 3:133,337,039...133,354,302
|
|
G |
Crp |
C-reactive protein |
multiple interactions increases secretion |
EXP |
Curcumin inhibits the reaction [lead acetate results in increased secretion of CRP protein] |
CTD |
PMID:21378372 |
|
NCBI chr13:85,131,635...85,175,179
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Crx |
cone-rod homeobox |
decreases expression |
EXP |
lead acetate results in decreased expression of CRX mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 1:76,540,141...76,545,818
Ensembl chr 1:76,540,141...76,545,818
|
|
G |
Cryab |
crystallin, alpha B |
increases expression |
ISO |
lead acetate results in increased expression of CRYAB mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Cryba1 |
crystallin, beta A1 |
increases expression |
ISO |
lead acetate results in increased expression of CRYBA1 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr10:62,608,373...62,614,726
Ensembl chr10:62,608,383...62,614,726
|
|
G |
Cryl1 |
crystallin, lambda 1 |
decreases expression |
ISO |
lead acetate results in decreased expression of CRYL1 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr15:31,427,011...31,545,997
Ensembl chr15:31,427,054...31,545,997
|
|
G |
Cryzl1 |
crystallin zeta like 1 |
increases expression |
ISO |
lead acetate results in increased expression of CRYZL1 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr11:30,933,140...30,977,936
Ensembl chr11:30,933,144...30,977,867
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
affects expression |
ISO |
lead acetate affects the expression of CSF1R mRNA |
CTD |
PMID:21829687 |
|
NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with lead acetate co-treated with CSF2 protein] results in increased expression of CD40 protein; [Lipopolysaccharides co-treated with lead acetate co-treated with CSF2 protein] results in increased expression of CD80 protein; [Lipopolysaccharides co-treated with lead acetate co-treated with CSF2 protein] results in increased expression of CD86 protein; [Lipopolysaccharides co-treated with lead acetate co-treated with CSF2 protein] results in increased expression of H2 protein; [Lipopolysaccharides co-treated with lead acetate co-treated with CSF2 protein] results in increased expression of ICAM1 protein; [Lipopolysaccharides co-treated with lead acetate co-treated with CSF2 protein] results in increased expression of IL10 protein; [Lipopolysaccharides co-treated with lead acetate co-treated with CSF2 protein] results in increased expression of IL6 protein; [Lipopolysaccharides co-treated with lead acetate co-treated with CSF2 protein] results in increased expression of TNF protein |
CTD |
PMID:17512567 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csf2ra |
colony stimulating factor 2 receptor subunit alpha |
increases expression |
ISO |
lead acetate results in increased expression of CSF2RA mRNA |
CTD |
PMID:21829687 |
|
NCBI chr14:98,089...103,261
Ensembl chr14:89,172...103,128
|
|
G |
Csnk2a2 |
casein kinase 2 alpha 2 |
increases expression |
ISO |
lead acetate results in increased expression of CSNK2A2 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr19:9,556,443...9,596,080
Ensembl chr19:9,556,260...9,596,080
|
|
G |
Cth |
cystathionine gamma-lyase |
multiple interactions decreases expression |
EXP |
sodium bisulfide inhibits the reaction [lead acetate results in decreased expression of CTH protein]; sodium boranocarbonate inhibits the reaction [lead acetate results in decreased expression of CTH protein] |
CTD |
PMID:30980911 |
|
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
|
|
G |
Ctnna3 |
catenin alpha 3 |
increases expression |
EXP |
lead acetate results in increased expression of CTNNA3 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr20:23,614,469...25,200,026
Ensembl chr20:23,623,560...25,199,978
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases phosphorylation multiple interactions |
EXP ISO |
lead acetate results in increased phosphorylation of CTNNB1 protein WNT7A protein inhibits the reaction [lead acetate results in increased phosphorylation of CTNNB1 protein] |
CTD |
PMID:24999626 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctps1 |
CTP synthase 1 |
decreases expression |
ISO |
lead acetate results in decreased expression of CTPS mRNA |
CTD |
PMID:22613225 |
|
NCBI chr 5:134,125,022...134,154,155
Ensembl chr 5:134,125,025...134,154,180
|
|
G |
Ctr9 |
CTR9 homolog, Paf1/RNA polymerase II complex component |
increases expression |
ISO |
lead acetate results in increased expression of CTR9 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 1:165,137,277...165,167,303
Ensembl chr 1:165,137,215...165,167,303
|
|
G |
Ctrc |
chymotrypsin C |
increases expression |
ISO |
lead acetate results in increased expression of CTRC mRNA |
CTD |
PMID:20542052 PMID:22609695 |
|
NCBI chr 5:154,147,314...154,156,540
Ensembl chr 5:154,147,316...154,156,528
|
|
G |
Ctrl |
chymotrypsin-like |
increases expression |
ISO |
lead acetate results in increased expression of CTRL mRNA |
CTD |
PMID:20542052 |
|
NCBI chr19:33,827,279...33,829,129
Ensembl chr19:33,827,229...33,833,626
|
|
G |
Ctsa |
cathepsin A |
increases expression |
EXP ISO |
lead acetate results in increased expression of CTSA mRNA |
CTD |
PMID:11578147 PMID:21829687 |
|
NCBI chr 3:153,569,106...153,574,983
Ensembl chr 3:153,568,381...153,576,215
|
|
G |
Ctsc |
cathepsin C |
decreases expression |
EXP |
lead acetate results in decreased expression of CTSC mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 1:142,028,386...142,059,841
Ensembl chr 1:142,028,392...142,060,387
|
|
G |
Ctsh |
cathepsin H |
increases expression |
ISO |
lead acetate results in increased expression of CTSH mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 8:90,608,941...90,627,824
Ensembl chr 8:90,608,941...90,627,824
|
|
G |
Ctso |
cathepsin O |
increases expression |
ISO |
lead acetate results in increased expression of CTSO mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 2:167,230,407...167,254,761
Ensembl chr 2:167,230,330...167,253,702
|
|
G |
Ctsz |
cathepsin Z |
increases expression |
ISO |
lead acetate results in increased expression of CTSZ mRNA |
CTD |
PMID:22613225 |
|
NCBI chr 3:163,224,875...163,235,645
Ensembl chr 3:163,224,875...163,235,645
|
|
G |
Cttn |
cortactin |
decreases expression |
ISO |
lead acetate results in decreased expression of CTTN mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164
|
|
G |
Cuzd1 |
CUB and zona pellucida-like domains 1 |
increases expression |
ISO |
lead acetate results in increased expression of CUZD1 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 1:186,089,422...186,130,536
Ensembl chr 1:186,089,423...186,102,546
|
|
G |
Cx3cl1 |
C-X3-C motif chemokine ligand 1 |
increases secretion |
EXP |
lead acetate results in increased secretion of CX3CL1 protein |
CTD |
PMID:17047031 |
|
NCBI chr19:10,227,337...10,237,826
Ensembl chr19:10,227,340...10,236,833
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
increases expression |
ISO |
lead acetate results in increased expression of CX3CR1 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014
|
|
G |
Cxcl17 |
C-X-C motif chemokine ligand 17 |
decreases expression |
EXP |
lead acetate results in decreased expression of CXCL17 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 1:80,984,751...80,996,842
Ensembl chr 1:80,984,964...80,996,726
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
multiple interactions affects expression |
ISO |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of CXCR4 mRNA lead acetate affects the expression of CXCR4 mRNA |
CTD |
PMID:12634122 PMID:21829687 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyb5b |
cytochrome b5 type B |
increases expression |
ISO |
lead acetate results in increased expression of CYB5B mRNA |
CTD |
PMID:21829687 |
|
NCBI chr19:35,062,871...35,096,741
Ensembl chr19:35,062,813...35,098,249
|
|
G |
Cybb |
cytochrome b-245 beta chain |
affects expression increases expression |
ISO EXP |
lead acetate affects the expression of CYBB mRNA lead acetate results in increased expression of CYBB mRNA lead acetate results in increased expression of CYBB protein |
CTD |
PMID:15569323 PMID:21829687 PMID:22641619 |
|
NCBI chr X:13,360,583...13,392,517
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions decreases expression decreases activity |
EXP ISO |
[cadmium acetate co-treated with lead acetate] results in decreased expression of CYP11A1 mRNA lead acetate results in decreased expression of CYP11A1 protein lead acetate results in decreased expression of CYP11A1 mRNA; lead acetate results in decreased expression of CYP11A1 protein lead acetate results in decreased activity of CYP11A1 protein |
CTD |
PMID:12647776 PMID:21182167 PMID:22806249 PMID:25270620 PMID:25981801 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
increases expression decreases expression |
ISO |
lead acetate results in increased expression of CYP17A1 mRNA lead acetate results in decreased expression of CYP17A1 mRNA; lead acetate results in decreased expression of CYP17A1 protein |
CTD |
PMID:21335049 PMID:22806249 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
EXP |
lead acetate results in decreased expression of CYP19A1 mRNA epigallocatechin gallate inhibits the reaction [lead acetate results in decreased expression of CYP19A1 mRNA] |
CTD |
PMID:31054310 |
|
NCBI chr 8:54,553,165...54,580,758
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
EXP |
lead acetate results in increased expression of CYP1B1 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
ISO |
lead acetate results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp27b1 |
cytochrome P450, family 27, subfamily b, polypeptide 1 |
decreases expression |
ISO |
lead acetate results in decreased expression of CYP27B1 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 7:62,869,340...62,876,242
Ensembl chr 7:62,871,297...62,876,241
|
|
G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
increases expression |
ISO |
lead acetate results in increased expression of CYP2A5 mRNA |
CTD |
PMID:30623991 |
|
NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
decreases expression |
ISO |
lead acetate results in decreased expression of CYP2B10 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression |
ISO |
lead acetate results in increased expression of CYP2B9 mRNA |
CTD |
PMID:21335049 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2r1 |
cytochrome P450, family 2, subfamily r, polypeptide 1 |
increases expression |
EXP |
lead acetate results in increased expression of CYP2R1 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 1:168,749,302...168,798,079
Ensembl chr 1:168,751,038...168,797,759
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases expression |
EXP |
lead acetate results in increased expression of CYP3A9 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp4f6 |
cytochrome P450, family 4, subfamily f, polypeptide 6 |
decreases expression |
ISO |
lead acetate results in decreased expression of CYP4F16 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 7:12,030,276...12,058,020
Ensembl chr 7:12,030,301...12,057,782
|
|
G |
Dab2 |
DAB adaptor protein 2 |
multiple interactions |
ISO |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of DAB2 mRNA |
CTD |
PMID:12634122 |
|
NCBI chr 2:55,514,692...55,567,476
Ensembl chr 2:55,514,700...55,567,476
|
|
G |
Dao |
D-amino-acid oxidase |
increases expression |
EXP ISO |
lead acetate results in increased expression of DAO mRNA lead acetate results in increased expression of DAO mRNA; lead acetate results in increased expression of DAO protein |
CTD |
PMID:11578147 PMID:25242007 |
|
NCBI chr12:42,592,342...42,613,046
Ensembl chr12:42,592,343...42,612,741
|
|
G |
Dapk1 |
death associated protein kinase 1 |
increases expression |
ISO |
lead acetate results in increased expression of DAPK1 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991
|
|
G |
Dapl1 |
death associated protein-like 1 |
decreases expression |
ISO |
lead acetate results in decreased expression of DAPL1 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 3:43,960,993...43,980,940
Ensembl chr 3:43,960,810...43,980,940
|
|
G |
Dars1 |
aspartyl-tRNA synthetase 1 |
increases expression |
EXP |
lead acetate results in increased expression of DARS mRNA |
CTD |
PMID:11578147 |
|
NCBI chr13:39,857,936...39,913,055
Ensembl chr13:39,857,936...39,913,116
|
|
G |
Dbf4 |
DBF4 zinc finger |
decreases expression |
ISO |
lead acetate results in decreased expression of DBF4 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 4:25,676,570...25,701,152
Ensembl chr 4:25,676,634...25,701,066
|
|
G |
Dbn1 |
drebrin 1 |
increases expression |
EXP |
lead acetate results in increased expression of DBN1 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984
|
|
G |
Dcstamp |
dendrocyte expressed seven transmembrane protein |
increases expression |
ISO |
lead acetate results in increased expression of DCSTAMP mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 7:70,807,455...70,822,067
Ensembl chr 7:70,807,581...70,822,078
|
|
G |
Dctn3 |
dynactin subunit 3 |
increases expression |
ISO |
lead acetate results in increased expression of DCTN3 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 5:56,881,085...56,889,041
Ensembl chr 5:56,881,085...56,889,102
|
|
G |
Dcun1d1 |
defective in cullin neddylation 1 domain containing 1 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of DCUN1D1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 2:118,721,275...118,772,606
Ensembl chr 2:118,721,822...118,772,602
|
|
G |
Dcxr |
dicarbonyl and L-xylulose reductase |
increases expression |
ISO |
lead acetate results in increased expression of DCXR mRNA |
CTD |
PMID:21829687 |
|
NCBI chr10:106,006,404...106,008,294
|
|
G |
Ddah1 |
dimethylarginine dimethylaminohydrolase 1 |
increases expression |
ISO EXP |
lead acetate results in increased expression of DDAH1 mRNA |
CTD |
PMID:11578147 PMID:20680508 |
|
NCBI chr 2:234,667,499...234,800,322
Ensembl chr 2:234,667,491...234,799,339
|
|
G |
Ddc |
dopa decarboxylase |
decreases expression |
EXP |
lead acetate results in decreased expression of DDC mRNA |
CTD |
PMID:22641619 |
|
NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO EXP |
lead acetate results in increased expression of DDIT3 mRNA lead acetate results in increased expression of DDIT3 protein |
CTD |
PMID:22811615 PMID:25270620 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression |
ISO |
lead acetate results in increased expression of DDIT4 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Ddr2 |
discoidin domain receptor tyrosine kinase 2 |
increases expression |
EXP |
lead acetate results in increased expression of DDR2 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr13:82,193,623...82,318,229
Ensembl chr13:82,195,463...82,317,363
|
|
G |
Ddx23 |
DEAD-box helicase 23 |
increases expression |
ISO |
lead acetate results in increased expression of DDX23 mRNA |
CTD |
PMID:22613225 |
|
NCBI chr 7:129,797,620...129,814,909
Ensembl chr 7:129,797,614...129,814,949
|
|
G |
Ddx39a |
DExD-box helicase 39A |
affects expression |
ISO |
lead acetate affects the expression of DDX39A mRNA |
CTD |
PMID:21829687 |
|
NCBI chr19:24,418,743...24,427,422
Ensembl chr19:24,418,114...24,426,954
|
|
G |
Ddx39b |
DExD-box helicase 39B |
decreases expression |
ISO |
lead acetate results in decreased expression of DDX39B mRNA |
CTD |
PMID:21829687 |
|
NCBI chr20:3,547,702...3,585,064
Ensembl chr20:3,572,056...3,584,996
|
|
G |
Ddx3y |
DEAD-box helicase 3, Y-linked |
increases expression decreases expression |
ISO |
lead acetate results in increased expression of DDX3Y mRNA lead acetate results in decreased expression of DDX3Y mRNA; lead acetate results in decreased expression of DDX3Y protein |
CTD |
PMID:22609695 PMID:24140753 |
|
NCBI chr13:98,520,538...98,523,707
Ensembl chr13:98,520,201...98,524,176
|
|
G |
Dedd2 |
death effector domain containing 2 |
increases expression |
ISO |
lead acetate results in increased expression of DEDD2 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 1:80,789,084...80,807,789
Ensembl chr 1:80,792,000...80,807,714
|
|
G |
Denr |
density regulated reinitiation and release factor |
increases expression |
ISO |
lead acetate results in increased expression of DENR mRNA |
CTD |
PMID:20542052 |
|
NCBI chr12:32,662,512...32,685,283
Ensembl chr12:32,662,516...32,683,843
|
|
G |
Dgcr6 |
DiGeorge syndrome critical region gene 6 |
increases expression |
ISO |
lead acetate results in increased expression of DGCR6 mRNA |
CTD |
PMID:22613225 |
|
NCBI chr11:82,927,725...82,932,823
Ensembl chr11:82,927,725...82,932,823
|
|
G |
Dgcr8 |
DGCR8 microprocessor complex subunit |
decreases expression |
EXP |
lead acetate results in decreased expression of DGCR8 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr11:82,704,673...82,737,251
Ensembl chr11:82,704,729...82,737,242
|
|
G |
Dgka |
diacylglycerol kinase, alpha |
increases expression |
EXP |
lead acetate results in increased expression of DGKA mRNA |
CTD |
PMID:11578147 |
|
NCBI chr 7:1,148,734...1,175,324
Ensembl chr 7:1,148,735...1,175,110
|
|
G |
Dhrs3 |
dehydrogenase/reductase 3 |
decreases expression |
EXP |
lead acetate results in decreased expression of DHRS3 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 5:156,747,939...156,782,420
Ensembl chr 5:156,747,962...156,782,417
|
|
G |
Dhx29 |
DExH-box helicase 29 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of DHX29 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 2:44,560,653...44,611,450
Ensembl chr 2:44,560,714...44,611,445
|
|
G |
Dhx58 |
DEXH-box helicase 58 |
increases expression |
ISO |
lead acetate results in increased expression of DHX58 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr10:85,620,352...85,631,776
Ensembl chr10:85,620,357...85,631,525
|
|
G |
Diaph2 |
diaphanous-related formin 2 |
increases expression |
ISO |
lead acetate results in increased expression of DIAPH2 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr X:92,395,189...93,234,521
Ensembl chr X:92,395,251...93,229,869
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
decreases expression |
ISO |
lead acetate results in decreased expression of DIO1 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
increases expression |
EXP |
lead acetate results in increased expression of DIO2 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dio3os |
DIO3 opposite strand upstream RNA |
decreases expression |
ISO |
lead acetate results in decreased expression of DIO3OS mRNA |
CTD |
PMID:27562236 |
|
|
|
G |
Disc1 |
DISC1 scaffold protein |
increases expression |
EXP |
lead acetate results in increased expression of DISC1 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr19:53,014,201...53,223,617
Ensembl chr19:53,014,616...53,219,778
|
|
G |
Disp3 |
dispatched RND transporter family member 3 |
increases expression |
ISO |
lead acetate results in increased expression of DISP3 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 5:158,672,015...158,720,806
Ensembl chr 5:158,672,015...158,720,806
|
|
G |
Dld |
dihydrolipoamide dehydrogenase |
decreases expression |
EXP |
lead acetate results in decreased expression of DLD protein |
CTD |
PMID:25981801 |
|
NCBI chr 6:47,904,153...47,924,814
Ensembl chr 6:47,903,914...47,924,795
|
|
G |
Dleu7 |
deleted in lymphocytic leukemia, 7 |
increases expression |
ISO |
lead acetate results in increased expression of DLEU7 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr15:36,479,535...36,496,069
Ensembl chr15:36,479,534...36,495,697
|
|
G |
Dlg4 |
discs large MAGUK scaffold protein 4 |
increases expression affects expression decreases expression |
EXP |
lead acetate results in increased expression of DLG4 mRNA lead acetate affects the expression of DLG4 protein lead acetate results in decreased expression of DLG4 protein |
CTD |
PMID:27492863 PMID:27984133 |
|
NCBI chr10:54,740,700...54,769,097
Ensembl chr10:54,739,470...54,767,153
|
|
G |
Dlg5 |
discs large MAGUK scaffold protein 5 |
decreases expression |
ISO |
lead acetate results in decreased expression of DLG5 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr15:75,786...209,735
Ensembl chr15:75,786...187,837
|
|
G |
Dlx2 |
distal-less homeobox 2 |
increases expression |
ISO |
lead acetate results in increased expression of DLX2 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 3:56,371,347...56,373,230
Ensembl chr 3:56,370,483...56,373,597
|
|
G |
Dmbt1 |
deleted in malignant brain tumors 1 |
increases expression decreases expression |
ISO |
lead acetate results in increased expression of DMBT1 mRNA lead acetate results in decreased expression of DMBT1 mRNA |
CTD |
PMID:20542052 PMID:22609695 |
|
NCBI chr 1:185,617,469...185,696,476
Ensembl chr 1:185,617,294...185,696,478
|
|
G |
Dmrt2 |
doublesex and mab-3 related transcription factor 2 |
decreases expression |
ISO |
lead acetate results in decreased expression of DMRT2 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 1:223,317,543...223,324,131
Ensembl chr 1:223,317,642...223,324,131
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
increases expression |
ISO |
lead acetate results in increased expression of DNAJB1 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr19:24,522,717...24,526,458
Ensembl chr19:24,522,717...24,526,458
|
|
G |
Dnajb6 |
DnaJ heat shock protein family (Hsp40) member B6 |
decreases expression |
ISO |
lead acetate results in decreased expression of DNAJB6 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 4:5,452,683...5,556,679
Ensembl chr 4:5,452,683...5,556,659
|
|
G |
Dnajc21 |
DnaJ heat shock protein family (Hsp40) member C21 |
decreases expression |
ISO |
lead acetate results in decreased expression of DNAJC21 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 2:59,419,505...59,446,743
Ensembl chr 2:59,419,510...59,446,752
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
decreases expression multiple interactions increases expression |
EXP ISO |
lead acetate results in decreased expression of DNMT1 mRNA; lead acetate results in decreased expression of DNMT1 protein [lead acetate results in increased abundance of Lead] which affects the expression of DNMT1 protein lead acetate results in increased expression of DNMT1 mRNA; lead acetate results in increased expression of DNMT1 protein |
CTD |
PMID:21117136 PMID:22160880 PMID:22764079 PMID:23246732 PMID:29481626 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
increases expression multiple interactions decreases expression |
EXP ISO |
lead acetate results in increased expression of DNMT3A protein [lead acetate results in increased abundance of Lead] which affects the expression of DNMT3A protein lead acetate results in decreased expression of DNMT3A protein |
CTD |
PMID:23246732 PMID:29481626 |
|
NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687
|
|
G |
Dnmt3l |
DNA methyltransferase 3 like |
increases methylation |
EXP |
lead acetate results in increased methylation of DNMT3L gene |
CTD |
PMID:29571894 |
|
NCBI chr20:10,614,933...10,629,516
Ensembl chr20:10,614,934...10,629,516
|
|
G |
Dnpep |
aspartyl aminopeptidase |
increases expression decreases expression |
ISO |
lead acetate results in increased expression of DNPEP mRNA lead acetate results in decreased expression of DNPEP mRNA |
CTD |
PMID:21829687 PMID:22609695 PMID:25270620 |
|
NCBI chr 9:76,799,931...76,808,841
Ensembl chr 9:76,783,966...76,808,716
|
|
G |
Dntt |
DNA nucleotidylexotransferase |
decreases expression |
ISO |
lead acetate results in decreased expression of DNTT mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 1:239,856,391...239,888,283
Ensembl chr 1:239,856,391...239,888,282
|
|
G |
Dock1 |
dedicator of cyto-kinesis 1 |
increases expression |
ISO |
lead acetate results in increased expression of DOCK1 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 1:189,467,143...189,983,777
Ensembl chr 1:189,467,143...189,983,768
|
|
G |
Dok2 |
docking protein 2 |
affects expression |
ISO |
lead acetate affects the expression of DOK2 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr15:45,826,984...45,841,409
Ensembl chr15:45,827,398...45,841,402
|
|
G |
Dok3 |
docking protein 3 |
increases expression |
ISO |
lead acetate results in increased expression of DOK3 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr17:9,109,633...9,115,188
Ensembl chr17:9,109,597...9,115,188
|
|
G |
Dpp4 |
dipeptidylpeptidase 4 |
decreases expression |
ISO |
lead acetate results in decreased expression of DPP4 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 3:46,962,243...47,043,870
Ensembl chr 3:46,962,243...47,043,901
|
|
G |
Dpt |
dermatopontin |
decreases expression |
EXP |
lead acetate results in decreased expression of DPT mRNA |
CTD |
PMID:22641619 |
|
NCBI chr13:77,122,926...77,151,646
Ensembl chr13:77,123,115...77,151,639
|
|
G |
Dpysl2 |
dihydropyrimidinase-like 2 |
increases expression |
ISO |
lead acetate results in increased expression of DPYSL2 protein |
CTD |
PMID:20797405 |
|
NCBI chr15:41,005,551...41,111,724
Ensembl chr15:41,005,551...41,111,829
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions increases expression |
EXP |
[lead acetate co-treated with Morphine] results in increased expression of DRD2 mRNA; [lead acetate co-treated with Morphine] results in increased expression of DRD2 protein lead acetate results in increased expression of DRD2 mRNA; lead acetate results in increased expression of DRD2 protein |
CTD |
PMID:23702354 |
|
NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Dsc1 |
desmocollin 1 |
decreases expression |
ISO |
lead acetate results in decreased expression of DSC1 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr18:11,499,936...11,556,801
Ensembl chr18:11,502,003...11,528,494
|
|
G |
Dsc2 |
desmocollin 2 |
decreases expression |
ISO |
lead acetate results in decreased expression of DSC2 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr18:11,450,392...11,482,476
Ensembl chr18:11,450,390...11,482,392
|
|
G |
Dsp |
desmoplakin |
decreases expression |
EXP |
lead acetate results in decreased expression of DSP mRNA |
CTD |
PMID:22641619 |
|
NCBI chr17:26,623,602...26,671,692
Ensembl chr17:26,623,588...26,671,800
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression decreases expression |
ISO EXP |
lead acetate results in increased expression of DUSP1 mRNA lead acetate results in decreased expression of DUSP1 mRNA |
CTD |
PMID:21829687 PMID:22641619 |
|
NCBI chr10:16,680,489...16,683,276
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
increases expression |
ISO |
lead acetate results in increased expression of DUSP10 mRNA |
CTD |
PMID:33932463 |
|
NCBI chr13:95,613,716...95,651,716
Ensembl chr13:95,614,292...95,651,716
|
|
G |
Dusp12 |
dual specificity phosphatase 12 |
decreases expression |
EXP |
lead acetate results in decreased expression of DUSP12 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr13:83,122,192...83,131,800
Ensembl chr13:83,122,193...83,131,285
|
|
G |
Dusp16 |
dual specificity phosphatase 16 |
decreases expression |
ISO |
lead acetate results in decreased expression of DUSP16 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 4:167,546,780...167,629,949
Ensembl chr 4:167,548,155...167,629,980
|
|
G |
Dusp23 |
dual specificity phosphatase 23 |
increases expression |
ISO |
lead acetate results in increased expression of DUSP23 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr13:85,098,792...85,099,984
Ensembl chr13:85,097,899...85,100,093
|
|
G |
Dync1li1 |
dynein cytoplasmic 1 light intermediate chain 1 |
increases methylation decreases expression |
EXP |
lead acetate results in increased methylation of DYNC1LI1 gene lead acetate results in decreased expression of DYNC1LI1 mRNA |
CTD |
PMID:29571894 |
|
NCBI chr 8:114,376,649...114,410,297
Ensembl chr 8:114,376,662...114,410,934
|
|
G |
Ears2 |
glutamyl-tRNA synthetase 2, mitochondrial |
increases expression |
ISO |
lead acetate results in increased expression of EARS2 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 1:176,597,986...176,625,848
Ensembl chr 1:176,597,986...176,625,836
|
|
G |
Ebpl |
EBP like |
decreases expression |
EXP |
lead acetate results in decreased expression of EBPL mRNA |
CTD |
PMID:22641619 |
|
NCBI chr15:35,508,074...35,531,472
Ensembl chr15:35,508,074...35,531,472
|
|
G |
Ednrb |
endothelin receptor type B |
increases expression |
ISO |
lead acetate results in increased expression of EDNRB mRNA |
CTD |
PMID:22839698 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Eea1 |
early endosome antigen 1 |
decreases methylation |
EXP |
lead acetate results in decreased methylation of EEA1 gene |
CTD |
PMID:29571894 |
|
NCBI chr 7:30,554,686...30,722,186
Ensembl chr 7:30,554,552...30,718,487
|
|
G |
Efcab2 |
EF-hand calcium binding domain 2 |
increases expression |
EXP |
lead acetate results in increased expression of EFCAB2 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr13:90,152,002...90,237,918
Ensembl chr13:90,152,185...90,238,218
|
|
G |
Egf |
epidermal growth factor |
increases expression |
ISO |
lead acetate results in increased expression of EGF mRNA |
CTD |
PMID:27562236 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression increases phosphorylation multiple interactions |
EXP ISO |
lead acetate results in decreased expression of EGFR protein lead acetate results in increased phosphorylation of EGFR protein 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [lead acetate results in increased phosphorylation of EGFR protein]; EGFR mutant form inhibits the reaction [lead acetate results in increased activity of PRKCA protein]; EGFR mutant form inhibits the reaction [lead acetate results in increased phosphorylation of SRC protein]; RTKI cpd inhibits the reaction [lead acetate results in increased phosphorylation of EGFR protein] |
CTD |
PMID:17298174 PMID:19133285 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egln3 |
egl-9 family hypoxia-inducible factor 3 |
decreases expression |
ISO |
lead acetate results in decreased expression of EGLN3 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 6:71,650,297...71,675,766
Ensembl chr 6:71,650,297...71,675,766
|
|
G |
Egr1 |
early growth response 1 |
decreases expression |
EXP |
lead acetate results in decreased expression of EGR1 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr2 |
early growth response 2 |
decreases expression increases methylation |
EXP |
lead acetate results in decreased expression of EGR2 mRNA lead acetate results in increased methylation of EGR2 gene |
CTD |
PMID:22641619 PMID:29571894 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Ehd2 |
EH-domain containing 2 |
increases expression |
ISO |
lead acetate results in increased expression of EHD2 mRNA |
CTD |
PMID:29746905 |
|
NCBI chr 1:76,639,568...76,658,747
Ensembl chr 1:76,637,482...76,658,783
|
|
G |
Eif1ax |
eukaryotic translation initiation factor 1A, X-linked |
decreases expression |
ISO |
lead acetate results in decreased expression of EIF1AX mRNA |
CTD |
PMID:21829687 |
|
NCBI chr X:35,498,698...35,513,402
Ensembl chr X:35,498,517...35,513,335
|
|
G |
Eif2ak2 |
eukaryotic translation initiation factor 2-alpha kinase 2 |
increases expression |
ISO |
lead acetate results in increased expression of EIF2AK2 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 6:16,189,000...16,224,972
Ensembl chr 6:16,188,979...16,224,971
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases phosphorylation multiple interactions |
EXP |
lead acetate results in increased phosphorylation of EIF2AK3 protein Proanthocyanidins inhibits the reaction [lead acetate results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:25088297 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2ak4 |
eukaryotic translation initiation factor 2 alpha kinase 4 |
decreases expression |
ISO |
lead acetate results in decreased expression of EIF2AK4 mRNA |
CTD |
PMID:22613225 |
|
NCBI chr 3:105,356,261...105,441,630
Ensembl chr 3:105,356,261...105,441,630
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation multiple interactions |
EXP |
lead acetate results in increased phosphorylation of EIF2S1 protein Proanthocyanidins inhibits the reaction [lead acetate results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:25088297 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Eif4a1 |
eukaryotic translation initiation factor 4A1 |
decreases expression |
ISO |
lead acetate results in decreased expression of EIF4A1 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr10:54,384,345...54,389,853
Ensembl chr10:54,384,347...54,389,858
|
|
G |
Eif4e3 |
eukaryotic translation initiation factor 4E family member 3 |
increases expression |
ISO |
lead acetate results in increased expression of EIF4E3 mRNA |
CTD |
PMID:22613225 |
|
NCBI chr 4:132,258,502...132,301,808
Ensembl chr 4:132,258,502...132,301,808
|
|
G |
Eif4g2 |
eukaryotic translation initiation factor 4, gamma 2 |
increases expression |
ISO |
lead acetate results in increased expression of EIF4G2 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 1:165,181,433...165,193,583
Ensembl chr 1:165,181,434...165,193,588
|
|
G |
Elavl4 |
ELAV like RNA binding protein 4 |
increases expression |
ISO |
lead acetate results in increased expression of ELAVL4 mRNA |
CTD |
PMID:24260418 |
|
NCBI chr 5:125,056,848...125,200,543
Ensembl chr 5:125,056,848...125,200,446
|
|
G |
Elf2 |
E74 like ETS transcription factor 2 |
increases expression |
ISO |
lead acetate results in increased expression of ELF2 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 2:135,292,291...135,385,942
Ensembl chr 2:135,294,906...135,385,947
|
|
G |
Elf5 |
E74 like ETS transcription factor 5 |
decreases expression |
ISO |
lead acetate results in decreased expression of ELF5 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 3:89,808,836...89,836,977
Ensembl chr 3:89,797,880...89,836,973
|
|
G |
Elovl1 |
ELOVL fatty acid elongase 1 |
increases expression |
EXP |
lead acetate results in increased expression of ELOVL1 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 5:131,961,478...131,965,961
Ensembl chr 5:131,961,322...131,965,958
|
|
G |
Emcn |
endomucin |
decreases expression |
EXP |
lead acetate results in decreased expression of EMCN mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 2:225,891,100...225,970,932
Ensembl chr 2:225,891,100...225,970,929
|
|
G |
Emg1 |
EMG1 N1-specific pseudouridine methyltransferase |
decreases expression |
ISO |
lead acetate results in decreased expression of EMG1 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 4:157,509,258...157,517,540
Ensembl chr 4:157,509,277...157,517,540
|
|
G |
Eml4 |
EMAP like 4 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of EML4 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 6:11,219,545...11,334,824
Ensembl chr 6:11,219,566...11,334,879
|
|
G |
Eno1 |
enolase 1 |
increases expression |
ISO |
lead acetate results in increased expression of ENO1 protein |
CTD |
PMID:20797405 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Eno3 |
enolase 3 |
increases expression |
ISO |
lead acetate results in increased expression of ENO3 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr10:55,370,531...55,375,921
Ensembl chr10:55,366,975...55,375,921
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
decreases expression |
EXP |
lead acetate results in decreased expression of ENPP2 mRNA |
CTD |
PMID:21864555 |
|
NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827
|
|
G |
Enpp6 |
ectonucleotide pyrophosphatase/phosphodiesterase 6 |
increases expression |
EXP |
lead acetate results in increased expression of ENPP6 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr16:45,165,883...45,294,126
Ensembl chr16:45,169,178...45,294,077
|
|
G |
Entpd5 |
ectonucleoside triphosphate diphosphohydrolase 5 |
increases expression |
ISO |
lead acetate results in increased expression of ENTPD5 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 6:104,019,095...104,055,311
Ensembl chr 6:104,019,185...104,055,530
|
|
G |
Entpd8 |
ectonucleoside triphosphate diphosphohydrolase 8 |
increases expression |
ISO |
lead acetate results in increased expression of ENTPD8 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 3:7,885,277...7,895,517
Ensembl chr 3:7,889,909...7,895,296
|
|
G |
Epb41l3 |
erythrocyte membrane protein band 4.1-like 3 |
multiple interactions |
ISO |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of EPB41L3 mRNA |
CTD |
PMID:12634122 |
|
NCBI chr 9:109,056,178...109,260,607
Ensembl chr 9:109,016,113...109,260,607
|
|
G |
Epha2 |
Eph receptor A2 |
increases expression |
EXP |
lead acetate results in increased expression of EPHA2 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr 5:153,605,644...153,634,115
Ensembl chr 5:153,605,644...153,634,117
|
|
G |
Epha5 |
EPH receptor A5 |
multiple interactions |
ISO |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of EPHA5 mRNA |
CTD |
PMID:12634122 |
|
NCBI chr14:23,653,393...24,020,135
Ensembl chr14:23,653,393...24,017,317
|
|
G |
Epha8 |
Eph receptor A8 |
increases expression |
EXP |
lead acetate results in increased expression of EPHA8 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 5:149,166,107...149,193,498
Ensembl chr 5:149,166,697...149,193,399
|
|
G |
Ephb1 |
Eph receptor B1 |
increases expression |
ISO |
lead acetate results in increased expression of EPHB1 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 8:102,507,549...102,944,839
Ensembl chr 8:102,507,549...102,944,839
|
|
G |
Ephb3 |
Eph receptor B3 |
decreases expression |
EXP |
lead acetate results in decreased expression of EPHB3 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr11:79,840,668...79,859,467
Ensembl chr11:79,840,668...79,859,370
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
affects expression |
EXP |
lead acetate affects the expression of EPHX2 mRNA |
CTD |
PMID:21864555 PMID:22641619 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Eprs |
glutamyl-prolyl-tRNA synthetase |
increases expression |
EXP |
lead acetate results in increased expression of EPRS mRNA |
CTD |
PMID:11578147 |
|
NCBI chr13:96,901,548...96,971,966
Ensembl chr13:96,901,575...96,971,966
|
|
G |
Epx |
eosinophil peroxidase |
decreases expression |
ISO |
lead acetate results in decreased expression of EPX mRNA |
CTD |
PMID:22609695 |
|
NCBI chr10:72,666,865...72,677,952
Ensembl chr10:72,666,865...72,677,952
|
|
G |
Eras |
ES cell expressed Ras |
decreases expression increases expression |
ISO |
lead acetate results in decreased expression of ERAS mRNA lead acetate results in increased expression of ERAS mRNA |
CTD |
PMID:22609695 PMID:25270620 |
|
NCBI chr X:14,573,987...14,578,455
Ensembl chr X:14,573,987...14,578,374
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
multiple interactions |
ISO |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ERBB3 mRNA |
CTD |
PMID:12634122 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
decreases expression |
EXP |
lead acetate results in decreased expression of ERCC1 mRNA |
CTD |
PMID:33862172 |
|
NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963
|
|
G |
Ercc2 |
ERCC excision repair 2, TFIIH core complex helicase subunit |
multiple interactions increases expression |
ISO |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ERCC2 mRNA lead acetate results in increased expression of ERCC2 mRNA |
CTD |
PMID:12634122 PMID:29746905 |
|
NCBI chr 1:79,033,342...79,047,102
Ensembl chr 1:79,033,326...79,047,102
|
|
G |
Ercc5 |
ERCC excision repair 5, endonuclease |
multiple interactions |
ISO |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ERCC5 mRNA |
CTD |
PMID:12634122 |
|
NCBI chr 9:46,309,477...46,354,478
Ensembl chr 9:46,309,389...46,354,472
|
|
G |
Eri2 |
ERI1 exoribonuclease family member 2 |
increases expression |
EXP |
lead acetate results in increased expression of ERI2 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 1:174,140,831...174,168,757
Ensembl chr 1:174,141,993...174,168,665
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
increases expression increases phosphorylation multiple interactions |
ISO EXP |
lead acetate results in increased expression of ERN1 mRNA lead acetate results in increased phosphorylation of ERN1 protein Proanthocyanidins inhibits the reaction [lead acetate results in increased phosphorylation of ERN1 protein] |
CTD |
PMID:21829687 PMID:25088297 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Esm1 |
endothelial cell-specific molecule 1 |
decreases expression |
EXP |
lead acetate results in decreased expression of ESM1 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 2:44,876,067...44,884,805
Ensembl chr 2:44,876,067...44,884,804
|
|
G |
Esrp2 |
epithelial splicing regulatory protein 2 |
increases expression |
ISO |
lead acetate results in increased expression of ESRP2 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr19:34,034,559...34,041,726
Ensembl chr19:34,034,559...34,041,726
|
|
G |
Etf1 |
eukaryotic translation termination factor 1 |
increases expression |
ISO |
lead acetate results in increased expression of ETF1 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr18:26,502,413...26,530,753
Ensembl chr18:26,504,080...26,530,810
|
|
G |
Etfb |
electron transfer flavoprotein subunit beta |
increases expression decreases expression |
ISO EXP |
lead acetate results in increased expression of ETFB mRNA lead acetate results in decreased expression of ETFB mRNA |
CTD |
PMID:20542052 PMID:22641619 |
|
NCBI chr 1:93,851,908...93,866,072
Ensembl chr 1:93,851,858...93,866,068
|
|
G |
Etfbkmt |
electron transfer flavoprotein subunit beta lysine methyltransferase |
increases expression |
EXP |
lead acetate results in increased expression of ETFBKMT mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 4:182,140,492...182,204,635
Ensembl chr 4:182,140,559...182,150,305
|
|
G |
Evl |
Enah/Vasp-like |
increases expression |
EXP |
lead acetate results in increased expression of EVL mRNA |
CTD |
PMID:11578147 |
|
NCBI chr 6:127,473,119...127,594,342
Ensembl chr 6:127,474,543...127,594,344
|
|
G |
Eya4 |
EYA transcriptional coactivator and phosphatase 4 |
increases expression |
EXP |
lead acetate results in increased expression of EYA4 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 1:22,172,275...22,415,978
Ensembl chr 1:22,172,275...22,415,976
|
|
G |
F13a1 |
coagulation factor XIII A1 chain |
increases expression |
ISO |
lead acetate results in increased expression of F13A1 mRNA |
CTD |
PMID:27562236 |
|
NCBI chr17:27,815,723...27,992,494
Ensembl chr17:27,815,702...27,992,700
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
decreases expression |
ISO |
lead acetate results in decreased expression of F2R mRNA |
CTD |
PMID:22613225 |
|
NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870
|
|
G |
F2rl2 |
coagulation factor II (thrombin) receptor-like 2 |
increases expression |
ISO |
lead acetate results in increased expression of F2RL2 mRNA |
CTD |
PMID:27562236 |
|
NCBI chr 2:26,972,054...26,977,098
Ensembl chr 2:26,972,054...26,977,098
|
|
G |
F5 |
coagulation factor V |
affects expression |
EXP |
lead acetate affects the expression of F5 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr13:76,513,463...76,583,106
Ensembl chr13:76,513,255...76,582,317
|
|
G |
Fa2h |
fatty acid 2-hydroxylase |
increases expression |
ISO |
lead acetate results in increased expression of FA2H mRNA |
CTD |
PMID:20542052 |
|
NCBI chr19:39,312,904...39,364,153
Ensembl chr19:39,312,906...39,364,153
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
decreases expression affects methylation increases expression |
ISO EXP |
lead acetate results in decreased expression of FABP4 mRNA lead acetate affects the methylation of FABP4 gene lead acetate results in increased expression of FABP4 mRNA |
CTD |
PMID:22609695 PMID:29571894 |
|
NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fabp9 |
fatty acid binding protein 9 |
increases expression multiple interactions |
ISO |
lead acetate results in increased expression of FABP9 mRNA [lead acetate results in increased abundance of Lead] which results in decreased expression of FABP9 protein |
CTD |
PMID:22609695 PMID:32142724 |
|
NCBI chr 2:91,591,842...91,595,873
Ensembl chr 2:91,592,298...91,595,873
|
|
G |
Fah |
fumarylacetoacetate hydrolase |
increases expression |
EXP |
lead acetate results in increased expression of FAH mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 1:138,548,830...138,571,599
Ensembl chr 1:138,548,834...138,571,505
|
|
G |
Fam114a1l1 |
family with sequence similarity 114, member A1-like 1 |
increases expression |
EXP |
lead acetate results in increased expression of FAM114A1L1 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 9:111,656,805...111,659,571
Ensembl chr 9:111,656,366...111,659,557
|
|
G |
Fam81b |
family with sequence similarity 81, member B |
decreases expression |
EXP |
lead acetate results in decreased expression of FAM81B mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 2:5,750,678...5,870,580
Ensembl chr 2:5,771,240...5,879,440
|
|
G |
Fam83d |
family with sequence similarity 83, member D |
increases expression |
EXP |
lead acetate results in increased expression of FAM83D mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 3:147,421,941...147,441,211
Ensembl chr 3:147,421,908...147,441,192
|
|
G |
Fan1 |
FANCD2 and FANCI associated nuclease 1 |
increases expression |
ISO |
lead acetate results in increased expression of FAN1 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 1:117,915,323...117,945,044
Ensembl chr 1:117,917,099...117,944,977
|
|
G |
Fanca |
FA complementation group A |
decreases expression |
ISO |
lead acetate results in decreased expression of FANCA mRNA |
CTD |
PMID:22609695 |
|
NCBI chr19:51,304,021...51,362,586
Ensembl chr19:51,304,021...51,362,527
|
|
G |
Farsa |
phenylalanyl-tRNA synthetase subunit alpha |
decreases expression |
EXP |
lead acetate results in decreased expression of FARSA mRNA |
CTD |
PMID:11578147 |
|
NCBI chr19:23,291,409...23,300,985
Ensembl chr19:23,268,869...23,300,980
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
[S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate affects the localization of and results in increased activity of FAS protein]; lead acetate affects the localization of and results in increased activity of FAS protein; S-allylcysteine inhibits the reaction [lead acetate affects the localization of and results in increased activity of FAS protein] |
CTD |
PMID:22033380 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
lead acetate results in increased expression of FASN mRNA |
CTD |
PMID:30623991 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fat1 |
FAT atypical cadherin 1 |
multiple interactions |
ISO |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of FAT1 mRNA |
CTD |
PMID:12634122 |
|
NCBI chr16:47,177,253...47,296,261
Ensembl chr16:47,177,248...47,296,107
|
|
G |
Fbl |
fibrillarin |
affects localization |
ISO |
lead acetate affects the localization of FBL protein |
CTD |
PMID:10942594 |
|
NCBI chr 1:83,469,832...83,478,932
Ensembl chr 1:83,469,832...83,478,932
|
|
G |
Fbln2 |
fibulin 2 |
decreases expression |
EXP |
lead acetate results in decreased expression of FBLN2 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 4:123,704,289...123,763,857
Ensembl chr 4:123,704,373...123,763,948
|
|
G |
Fbn1 |
fibrillin 1 |
increases expression |
ISO |
lead acetate results in increased expression of FBN1 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 3:112,554,257...112,750,835
Ensembl chr 3:112,554,925...112,750,889
|
|
G |
Fbxl3 |
F-box and leucine-rich repeat protein 3 |
decreases expression |
ISO |
lead acetate results in decreased expression of FBXL3 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr15:79,906,795...79,926,678
Ensembl chr15:79,906,795...79,927,867
|
|
G |
Fbxl6 |
F-box and leucine-rich repeat protein 6 |
decreases expression |
ISO |
lead acetate results in decreased expression of FBXL6 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 7:108,259,097...108,262,528
Ensembl chr 7:108,257,160...108,262,513
|
|
G |
Fbxo32 |
F-box protein 32 |
increases expression |
ISO |
lead acetate results in increased expression of FBXO32 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 7:89,731,626...89,764,761
Ensembl chr 7:89,730,232...89,765,436
|
|
G |
Fbxo33 |
F-box protein 33 |
increases expression |
ISO |
lead acetate results in increased expression of FBXO33 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 6:76,900,619...76,934,232
Ensembl chr 6:76,900,631...76,932,669
|
|
G |
Fbxw12 |
F-box and WD repeat domain containing 12 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of FBXW12 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 8:109,782,315...109,802,086
Ensembl chr 8:109,786,815...109,801,813
|
|
G |
Fcer2 |
Fc epsilon receptor II |
increases expression |
ISO |
lead acetate results in increased expression of FCER2A mRNA |
CTD |
PMID:21829687 |
|
NCBI chr12:1,742,809...1,754,476
Ensembl chr12:1,742,815...1,754,476
|
|
G |
Fcgr2a |
Fc gamma receptor 2A |
affects binding |
ISO |
lead acetate binds to FCGR3 protein |
CTD |
PMID:10666595 |
|
NCBI chr13:83,280,782...83,297,535
Ensembl chr13:83,280,784...83,295,967
|
|
G |
Fcgr3a |
Fc gamma receptor 3A |
decreases expression |
ISO |
lead acetate results in decreased expression of FCGR4 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr13:83,249,905...83,259,921
Ensembl chr13:83,249,872...83,259,921
|
|
G |
Fcgrt |
Fc gamma receptor and transporter |
decreases expression |
ISO |
lead acetate results in decreased expression of FCGRT mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 1:95,574,436...95,584,171
Ensembl chr 1:95,567,175...95,584,084
|
|
G |
Fcrl2 |
Fc receptor-like 2 |
decreases expression |
EXP |
lead acetate results in decreased expression of FCRLS mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 2:172,694,308...172,707,261
Ensembl chr 2:172,694,308...172,707,051
|
|
G |
Fermt1 |
FERM domain containing kindlin 1 |
decreases expression |
EXP |
lead acetate results in decreased expression of FERMT1 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 3:120,171,301...120,213,555
Ensembl chr 3:120,171,561...120,213,555
|
|
G |
Fga |
fibrinogen alpha chain |
decreases expression |
ISO |
lead acetate results in decreased expression of FGA mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:168,365,364...168,381,533
Ensembl chr 2:168,374,120...168,381,528
|
|
G |
Fgb |
fibrinogen beta chain |
decreases expression |
ISO |
lead acetate results in decreased expression of FGB mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
affects expression |
EXP |
lead acetate affects the expression of FGF1 mRNA |
CTD |
PMID:21864555 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fgf18 |
fibroblast growth factor 18 |
decreases expression |
ISO |
lead acetate results in decreased expression of FGF18 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr10:17,706,011...17,737,702
Ensembl chr10:17,706,174...17,736,818
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
decreases expression |
EXP |
lead acetate results in decreased expression of FGF2 mRNA |
CTD |
PMID:22160880 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf21 |
fibroblast growth factor 21 |
increases expression |
ISO |
lead acetate results in increased expression of FGF21 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 1:96,083,495...96,084,738
Ensembl chr 1:96,083,441...96,090,454
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of FGFR1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr16:66,492,445...66,546,731
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fgfr4 |
fibroblast growth factor receptor 4 |
decreases expression |
ISO |
lead acetate results in decreased expression of FGFR4 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242
|
|
G |
Fgg |
fibrinogen gamma chain |
decreases expression |
ISO |
lead acetate results in decreased expression of FGG mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:168,354,880...168,362,325
Ensembl chr 2:168,355,013...168,362,322
|
|
G |
Fhip1a |
FHF complex subunit HOOK interacting protein 1A |
decreases expression |
EXP |
lead acetate results in decreased expression of FHIP1A mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 2:171,016,951...171,265,715
Ensembl chr 2:171,021,246...171,265,848
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
increases expression increases methylation |
EXP |
lead acetate results in increased expression of FKBP5 mRNA lead acetate results in increased methylation of FKBP5 gene |
CTD |
PMID:22641619 PMID:29571894 |
|
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
|
|
G |
Flg2 |
filaggrin 2 |
decreases expression |
EXP |
lead acetate results in decreased expression of FLG2 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 2:178,789,792...178,802,232
|
|
G |
Flt4 |
Fms related receptor tyrosine kinase 4 |
increases expression |
EXP |
lead acetate results in increased expression of FLT4 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr10:33,913,725...33,954,770
Ensembl chr10:33,913,608...33,954,770
|
|
G |
Fmnl3 |
formin-like 3 |
decreases expression |
ISO |
lead acetate results in decreased expression of FMNL3 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 7:130,454,270...130,505,621
Ensembl chr 7:130,454,275...130,505,626
|
|
G |
Fmo2 |
flavin containing dimethylaniline monoxygenase 2 |
decreases expression |
ISO |
lead acetate results in decreased expression of FMO2 mRNA |
CTD |
PMID:29746905 |
|
NCBI chr13:75,221,149...75,244,377
Ensembl chr13:75,224,402...75,244,308
|
|
G |
Fmo5 |
flavin containing dimethylaniline monoxygenase 5 |
decreases expression |
ISO |
lead acetate results in decreased expression of FMO5 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 2:185,197,184...185,249,699
Ensembl chr 2:185,222,204...185,249,693
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
increases methylation |
EXP |
lead acetate results in increased methylation of FMR1 gene |
CTD |
PMID:29571894 |
|
NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050
|
|
G |
Fn1 |
fibronectin 1 |
increases expression |
EXP |
lead acetate results in increased expression of FN1 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fndc3a |
fibronectin type III domain containing 3a |
increases expression |
ISO |
lead acetate results in increased expression of FNDC3A mRNA |
CTD |
PMID:22609695 |
|
NCBI chr15:47,689,909...47,867,354
Ensembl chr15:47,689,919...47,866,784
|
|
G |
Folh1 |
folate hydrolase 1 |
increases methylation |
EXP |
lead acetate results in increased methylation of FOLH1 gene |
CTD |
PMID:29571894 |
|
NCBI chr 1:140,428,101...140,501,563
Ensembl chr 1:140,428,101...140,501,379
|
|
G |
Folr1 |
folate receptor alpha |
affects expression |
EXP |
lead acetate affects the expression of FOLR1 mRNA |
CTD |
PMID:21864555 PMID:22641619 |
|
NCBI chr 1:156,219,460...156,238,436
Ensembl chr 1:156,219,460...156,230,667
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases expression increases expression |
EXP ISO |
lead acetate affects the reaction [Amphetamine results in increased expression of FOS protein]; lead acetate inhibits the reaction [HSPA5 protein binds to FOS enhancer] lead acetate results in decreased expression of FOS mRNA lead acetate results in increased expression of FOS protein |
CTD |
PMID:15111246 PMID:15111640 PMID:21829687 PMID:22641619 PMID:33862172 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in increased expression of FOSL1 mRNA |
CTD |
PMID:12634122 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Foxd4 |
forkhead box D4 |
increases expression |
ISO |
lead acetate results in increased expression of FOXD4 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 1:222,557,494...222,559,189
Ensembl chr 1:222,557,360...222,559,159
|
|
G |
Foxp2 |
forkhead box P2 |
decreases expression |
ISO |
lead acetate results in decreased expression of FOXP2 mRNA |
CTD |
PMID:22613225 |
|
NCBI chr 4:43,133,827...43,712,442
Ensembl chr 4:43,133,912...43,711,683
|
|
G |
Foxp3 |
forkhead box P3 |
increases expression |
ISO EXP |
lead acetate results in increased expression of FOXP3 mRNA lead acetate results in increased expression of FOXP3 protein |
CTD |
PMID:20542052 PMID:23058909 |
|
NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838
|
|
G |
Frem2 |
FRAS1 related extracellular matrix 2 |
increases expression |
ISO |
lead acetate results in increased expression of FREM2 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 2:137,602,784...137,740,785
Ensembl chr 2:137,602,784...137,740,785
|
|
G |
Frk |
fyn-related Src family tyrosine kinase |
increases expression |
EXP |
lead acetate results in increased expression of FRK mRNA |
CTD |
PMID:11578147 |
|
NCBI chr20:38,265,416...38,371,038
Ensembl chr20:38,265,280...38,371,114
|
|
G |
Frmd3 |
FERM domain containing 3 |
decreases expression |
ISO |
lead acetate results in decreased expression of FRMD3 mRNA |
CTD |
PMID:22613225 |
|
NCBI chr 5:87,764,604...88,032,261
Ensembl chr 5:87,764,604...88,031,091
|
|
G |
Frmd4b |
FERM domain containing 4B |
decreases expression |
ISO |
lead acetate results in decreased expression of FRMD4B mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 4:129,895,401...130,222,070
Ensembl chr 4:129,895,708...130,084,197
|
|
G |
Fry |
FRY microtubule binding protein |
increases expression |
ISO |
lead acetate results in increased expression of FRY mRNA |
CTD |
PMID:21829687 |
|
NCBI chr12:4,493,890...4,887,118
Ensembl chr12:4,493,891...4,799,116
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions decreases secretion |
EXP |
Cholecalciferol inhibits the reaction [lead acetate results in decreased secretion of FSHB protein] |
CTD |
PMID:34051273 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fth1 |
ferritin heavy chain 1 |
increases expression |
ISO |
lead acetate results in increased expression of FTH1 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Ftl1 |
ferritin light chain 1 |
increases expression |
EXP ISO |
lead acetate results in increased expression of FTL mRNA |
CTD |
PMID:11578147 PMID:27562236 |
|
NCBI chr 1:95,936,390...95,938,234
Ensembl chr 1:95,936,387...95,939,725
|
|
G |
Fut4 |
fucosyltransferase 4 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of FUT4 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 8:11,586,721...11,590,682
Ensembl chr 8:11,586,721...11,590,682
|
|
G |
Fyb2 |
FYN binding protein 2 |
decreases expression |
EXP |
lead acetate results in decreased expression of FYB2 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 5:119,677,116...119,800,911
Ensembl chr 5:119,677,204...119,800,910
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
multiple interactions increases activity |
EXP |
FYN protein affects the reaction [lead acetate results in decreased expression of PDGFRA protein] lead acetate results in increased activity of FYN protein |
CTD |
PMID:17298174 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases activity multiple interactions |
EXP |
lead acetate results in decreased activity of G6PD protein [naringenin co-treated with lead acetate] results in decreased activity of G6PD protein |
CTD |
PMID:25228019 PMID:30980912 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gaa |
alpha glucosidase |
increases expression |
EXP |
lead acetate results in increased expression of GAA mRNA |
CTD |
PMID:11578147 |
|
NCBI chr10:104,529,673...104,546,836
Ensembl chr10:104,529,747...104,546,836
|
|
G |
Gab2 |
GRB2-associated binding protein 2 |
increases expression |
ISO |
lead acetate results in increased expression of GAB2 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 1:151,429,844...151,625,708
Ensembl chr 1:151,429,695...151,625,031
|
|
G |
Gabrq |
gamma-aminobutyric acid type A receptor subunit theta |
decreases expression |
EXP |
lead acetate results in decreased expression of GABRQ mRNA |
CTD |
PMID:22641619 |
|
NCBI chr X:150,696,174...150,712,950
Ensembl chr X:150,696,427...150,709,919
|
|
G |
Gabrr1 |
gamma-aminobutyric acid type A receptor subunit rho 1 |
decreases expression |
EXP |
lead acetate results in decreased expression of GABRR1 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 5:47,524,151...47,561,228
Ensembl chr 5:47,524,151...47,561,228
|
|
G |
Gad2 |
glutamate decarboxylase 2 |
multiple interactions |
EXP |
[lead acetate results in increased abundance of Lead] which results in increased expression of GAD2 protein |
CTD |
PMID:31785328 |
|
NCBI chr17:84,763,630...84,826,155
Ensembl chr17:84,763,628...84,826,155
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
increases methylation |
EXP |
lead acetate results in increased methylation of GADD45G gene |
CTD |
PMID:29571894 |
|
NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610
|
|
G |
Galns |
galactosamine (N-acetyl)-6-sulfatase |
decreases expression |
ISO |
lead acetate results in decreased expression of GALNS mRNA |
CTD |
PMID:21829687 |
|
NCBI chr19:50,628,639...50,662,477
Ensembl chr19:50,628,552...50,662,246
|
|
G |
Galnt9 |
polypeptide N-acetylgalactosaminyltransferase 9 |
increases methylation |
EXP |
lead acetate results in increased methylation of GALNT9 gene |
CTD |
PMID:29571894 |
|
NCBI chr12:46,050,395...46,128,626
Ensembl chr12:46,050,413...46,128,578
|
|
G |
Galr1 |
galanin receptor 1 |
decreases expression |
EXP ISO |
lead acetate results in decreased expression of GALR1 mRNA |
CTD |
PMID:22609695 PMID:22641619 |
|
NCBI chr18:75,772,021...75,787,577
Ensembl chr18:75,772,023...75,787,577
|
|
G |
Galr2 |
galanin receptor 2 |
increases expression |
ISO |
lead acetate results in increased expression of GALR2 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr10:101,513,689...101,517,176
Ensembl chr10:101,514,471...101,517,176
|
|
G |
Gap43 |
growth associated protein 43 |
multiple interactions |
ISO |
[lead acetate results in increased abundance of Lead] promotes the reaction [[APP protein co-treated with APP protein modified form] results in decreased expression of GAP43 protein]; [lead acetate results in increased abundance of Lead] promotes the reaction [APP protein modified form results in decreased expression of GAP43 protein]; [lead acetate results in increased abundance of Lead] promotes the reaction [APP protein results in decreased expression of GAP43 protein]; [lead acetate results in increased abundance of Lead] which results in decreased expression of GAP43 protein |
CTD |
PMID:31843630 |
|
NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
increases expression |
ISO |
lead acetate results in increased expression of GAPDH protein |
CTD |
PMID:20797405 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gast |
gastrin |
increases expression multiple interactions |
ISO |
lead acetate results in increased expression of GAST mRNA; lead acetate results in increased expression of GAST protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lead acetate results in increased expression of GAST mRNA]; 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [lead acetate results in increased expression of GAST mRNA]; RTKI cpd inhibits the reaction [lead acetate results in increased expression of GAST mRNA] |
CTD |
PMID:23765435 |
|
NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496
|
|
G |
Gata2 |
GATA binding protein 2 |
decreases expression |
ISO |
lead acetate results in decreased expression of GATA2 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761
|
|
G |
Gata3 |
GATA binding protein 3 |
decreases expression |
ISO |
lead acetate results in decreased expression of GATA3 mRNA |
CTD |
PMID:22613225 |
|
NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391
|
|
G |
Gata6 |
GATA binding protein 6 |
multiple interactions |
ISO |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of GATA6 mRNA |
CTD |
PMID:12634122 |
|
NCBI chr18:2,188,121...2,219,532
Ensembl chr18:2,188,121...2,219,532
|
|
G |
Gatm |
glycine amidinotransferase |
decreases expression |
ISO |
lead acetate results in decreased expression of GATM mRNA |
CTD |
PMID:20542052 |
|
NCBI chr 3:109,658,919...109,675,508
Ensembl chr 3:109,658,951...109,684,129
|
|
G |
Gbp6 |
guanylate binding protein family member 6 |
increases expression |
ISO |
lead acetate results in increased expression of GBP6 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr14:4,730,286...4,756,508
Ensembl chr14:4,730,453...4,839,062
|
|
G |
Gbx2 |
gastrulation brain homeobox 2 |
decreases expression |
ISO |
lead acetate results in decreased expression of GBX2 mRNA |
CTD |
PMID:22613225 PMID:25270620 |
|
NCBI chr 9:90,509,633...90,512,212
Ensembl chr 9:90,509,633...90,512,212
|
|
G |
Gc |
GC, vitamin D binding protein |
increases expression |
EXP |
lead acetate results in increased expression of GC mRNA |
CTD |
PMID:22641619 |
|
NCBI chr14:18,632,146...18,667,563
Ensembl chr14:18,632,135...18,667,567
|
|
G |
Gch1 |
GTP cyclohydrolase 1 |
decreases expression increases expression |
EXP ISO |
lead acetate results in decreased expression of GCH1 mRNA lead acetate results in increased expression of GCH1 mRNA |
CTD |
PMID:22641619 PMID:25270620 |
|
NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
ISO |
NFE2L2 mutant form inhibits the reaction [lead acetate results in increased expression of GCLC mRNA] |
CTD |
PMID:26498409 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression multiple interactions |
ISO |
lead acetate results in increased expression of GCLM mRNA NFE2L2 mutant form inhibits the reaction [lead acetate results in increased expression of GCLM mRNA] |
CTD |
PMID:25270620 PMID:26498409 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gcnt3 |
glucosaminyl (N-acetyl) transferase 3, mucin type |
increases expression |
ISO |
lead acetate results in increased expression of GCNT3 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 8:70,689,173...70,696,476
Ensembl chr 8:70,686,844...70,699,562
|
|
G |
Gcnt4 |
glucosaminyl (N-acetyl) transferase 4 |
increases expression |
EXP |
lead acetate results in increased expression of GCNT4 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 2:28,253,311...28,329,381
Ensembl chr 2:28,252,860...28,283,082
|
|
G |
Gdap2 |
ganglioside-induced differentiation-associated-protein 2 |
decreases expression |
ISO |
lead acetate results in decreased expression of GDAP2 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 2:187,528,514...187,585,270
Ensembl chr 2:187,528,513...187,585,270
|
|
G |
Gdf15 |
growth differentiation factor 15 |
multiple interactions |
ISO |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of GDF15 mRNA |
CTD |
PMID:12634122 |
|
NCBI chr16:18,805,312...18,807,893
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gdf2 |
growth differentiation factor 2 |
increases expression |
ISO |
lead acetate results in increased expression of GDF2 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr16:9,255,430...9,261,429
Ensembl chr16:9,255,430...9,261,429
|
|
G |
Gdf5 |
growth differentiation factor 5 |
increases expression |
ISO |
lead acetate results in increased expression of GDF5 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 3:144,454,306...144,458,757
Ensembl chr 3:144,454,338...144,458,612
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions increases expression decreases expression |
EXP ISO |
[[sodium arsenite co-treated with lead acetate co-treated with Cadmium Chloride] results in increased phosphorylation of and results in increased activity of PPARG protein] which results in decreased expression of GFAP protein; [Cadmium Chloride co-treated with sodium arsenite co-treated with lead acetate] results in decreased expression of GFAP protein; [lead acetate co-treated with Morphine] results in increased expression of GFAP mRNA; [sodium arsenite co-treated with Cadmium Chloride co-treated with lead acetate] results in increased expression of GFAP protein; [sodium arsenite co-treated with lead acetate co-treated with Cadmium Chloride] promotes the reaction [PPARG protein binds to GFAP promoter]; [sodium arsenite co-treated with lead acetate co-treated with Cadmium Chloride] results in decreased expression of GFAP mRNA; [sodium arsenite co-treated with lead acetate co-treated with Cadmium Chloride] results in decreased expression of GFAP protein; CR8 compound inhibits the reaction [[sodium arsenite co-treated with lead acetate co-treated with Cadmium Chloride] results in decreased expression of GFAP protein] lead acetate results in increased expression of GFAP mRNA; lead acetate results in increased expression of GFAP protein lead acetate results in decreased expression of GFAP protein |
CTD |
PMID:17047031 PMID:20829427 PMID:21322097 PMID:24481447 PMID:26396915 PMID:26478469 PMID:33862172 More...
|
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Ggct |
gamma-glutamyl cyclotransferase |
increases expression |
ISO |
lead acetate results in increased expression of GGCT mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 4:84,122,921...84,129,327
Ensembl chr 4:84,123,118...84,129,277
|
|
G |
Ghitm |
growth hormone inducible transmembrane protein |
increases expression |
ISO |
lead acetate results in increased expression of GHITM mRNA |
CTD |
PMID:25270620 |
|
NCBI chr16:12,885,551...12,897,887
Ensembl chr16:12,885,553...12,897,879
|
|
G |
Gimap7 |
GTPase, IMAP family member 7 |
increases expression |
ISO |
lead acetate results in increased expression of GIMAP7 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 4:77,670,522...77,674,692
Ensembl chr 4:77,670,367...77,675,272
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases expression increases uptake multiple interactions decreases expression |
EXP |
lead acetate results in increased expression of GJA1 protein GJA1 protein results in increased uptake of lead acetate 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lead acetate results in decreased expression of GJA1 protein]; 3-methyladenine inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of GJA1 protein]; [lead acetate results in increased abundance of Lead] which results in decreased expression of and affects the localization of GJA1 protein; Dasatinib promotes the reaction [lead acetate results in decreased expression of GJA1 protein]; GJA1 protein inhibits the reaction [Carbenoxolone results in decreased uptake of lead acetate] |
CTD |
PMID:20932874 PMID:26926986 PMID:28916327 PMID:29457680 PMID:33242459 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gja8 |
gap junction protein, alpha 8 |
increases expression |
ISO |
lead acetate results in increased expression of GJA8 mRNA |
CTD |
PMID:22609695 |
|
NCBI chr 2:184,490,840...184,492,456
Ensembl chr 2:184,490,840...184,492,456
|
|
G |
Gjb6 |
gap junction protein, beta 6 |
increases expression |
EXP |
lead acetate results in increased expression of GJB6 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr15:31,284,562...31,295,010
Ensembl chr15:31,284,419...31,294,582
|
|
G |
Gjc2 |
gap junction protein, gamma 2 |
increases expression |
EXP ISO |
lead acetate results in increased expression of GJC2 mRNA |
CTD |
PMID:22609695 PMID:22641619 |
|
NCBI chr10:43,962,642...43,971,358
Ensembl chr10:43,962,642...43,970,467
|
|
G |
Gjc3 |
gap junction protein, gamma 3 |
increases expression |
EXP |
lead acetate results in increased expression of GJC3 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr12:16,899,846...16,912,309
Ensembl chr12:16,896,813...16,964,246
|
|
G |
Gk |
glycerol kinase |
increases expression |
EXP |
lead acetate results in increased expression of GK mRNA |
CTD |
PMID:11578147 |
|
NCBI chr X:50,162,089...50,238,707
Ensembl chr X:50,163,123...50,238,631
|
|
G |
Gldn |
gliomedin |
increases expression |
EXP |
lead acetate results in increased expression of GLDN mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 8:54,679,015...54,723,198
Ensembl chr 8:54,679,119...54,723,196
|
|
G |
Gli1 |
GLI family zinc finger 1 |
multiple interactions |
ISO |
[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of GLI1 mRNA |
CTD |
PMID:12634122 |
|
NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251
|
|
G |
Glipr2 |
GLI pathogenesis-related 2 |
increases expression |
ISO |
lead acetate results in increased expression of GLIPR2 mRNA |
CTD |
PMID:25270620 |
|
NCBI chr 5:58,170,417...58,200,947
Ensembl chr 5:58,170,425...58,202,272
|
|
G |
Glod4 |
glyoxalase domain containing 4 |
increases expression |
ISO |
lead acetate results in increased expression of GLOD4 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr10:61,077,535...61,095,876
Ensembl chr10:61,066,421...61,095,898
|
|
G |
Glra2 |
glycine receptor, alpha 2 |
decreases expression |
EXP ISO |
lead acetate results in decreased expression of GLRA2 mRNA |
CTD |
PMID:22613225 PMID:22641619 |
|
NCBI chr X:29,020,377...29,241,666
Ensembl chr X:29,020,557...29,241,666
|
|
G |
Glra3 |
glycine receptor, alpha 3 |
decreases expression |
EXP |
lead acetate results in decreased expression of GLRA3 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr16:34,205,431...34,848,332
Ensembl chr16:34,204,811...34,848,753
|
|
G |
Glul |
glutamate-ammonia ligase |
increases expression multiple interactions decreases expression |
ISO EXP |
lead acetate results in increased expression of GLUL mRNA [sodium arsenite co-treated with lead acetate co-treated with Cadmium Chloride] results in decreased expression of GLUL protein lead acetate results in decreased expression of GLUL mRNA |
CTD |
PMID:20542052 PMID:23680456 PMID:25270620 |
|
NCBI chr13:65,969,064...66,035,121
Ensembl chr13:66,025,630...66,035,108
|
|
G |
Gmnn |
geminin, DNA replication inhibitor |
decreases expression |
ISO |
lead acetate results in decreased expression of GMNN mRNA |
CTD |
PMID:25270620 |
|
NCBI chr17:40,301,771...40,310,054
Ensembl chr17:40,301,808...40,310,054
|
|
G |
Gna13 |
G protein subunit alpha 13 |
increases expression |
ISO |
lead acetate results in increased expression of GNA13 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr10:94,337,939...94,370,774
Ensembl chr10:94,337,725...94,370,774
|
|
G |
Gnao1 |
G protein subunit alpha o1 |
increases expression |
ISO |
lead acetate results in increased expression of GNAO1 protein |
CTD |
PMID:20797405 |
|
NCBI chr19:11,034,874...11,192,502
Ensembl chr19:11,035,956...11,192,493
|
|
G |
Gnb4 |
G protein subunit beta 4 |
increases expression |
ISO |
lead acetate results in increased expression of GNB4 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 2:115,360,746...115,400,680
Ensembl chr 2:115,364,918...115,400,579
|
|
G |
Gng12 |
G protein subunit gamma 12 |
decreases expression |
ISO |
lead acetate results in decreased expression of GNG12 mRNA |
CTD |
PMID:22613225 |
|
NCBI chr 4:96,011,118...96,134,767
Ensembl chr 4:96,010,952...96,134,712
|
|
G |
Gngt2 |
G protein subunit gamma transducin 2 |
decreases expression |
EXP |
lead acetate results in decreased expression of GNGT2 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr10:80,776,003...80,784,235
|
|
G |
Golph3 |
golgi phosphoprotein 3 |
increases methylation decreases expression |
EXP |
lead acetate results in increased methylation of GOLPH3 gene lead acetate results in decreased expression of GOLPH3 mRNA |
CTD |
PMID:29571894 |
|
NCBI chr 2:61,348,030...61,376,051
Ensembl chr 2:61,348,030...61,376,049
|
|
G |
Gosr2 |
golgi SNAP receptor complex member 2 |
increases expression |
EXP |
lead acetate results in increased expression of GOSR2 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr10:88,585,291...88,605,642
Ensembl chr10:88,586,299...88,605,625
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions increases expression |
ISO |
[S-allylcysteine co-treated with Clotrimazole] inhibits the reaction [lead acetate results in increased expression of GOT1 protein] |
CTD |
PMID:22033380 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Got2 |
glutamic-oxaloacetic transaminase 2 |
increases expression |
EXP |
lead acetate results in increased expression of GOT2 mRNA |
CTD |
PMID:11578147 |
|
NCBI chr19:9,174,304...9,199,995
Ensembl chr19:9,174,311...9,199,994
|
|
G |
Gpat4 |
glycerol-3-phosphate acyltransferase 4 |
increases expression |
ISO |
lead acetate results in increased expression of GPAT4 mRNA |
CTD |
PMID:20542052 |
|
NCBI chr16:68,819,031...68,852,903
Ensembl chr16:68,819,079...68,852,901
|
|
G |
Gpatch4 |
G patch domain containing 4 |
increases expression |
EXP |
lead acetate results in increased expression of GPATCH4 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 2:173,499,700...173,520,346
Ensembl chr 2:173,509,897...173,518,684
|
|
G |
Gpd1 |
glycerol-3-phosphate dehydrogenase 1 |
increases expression |
EXP |
lead acetate results in increased expression of GPD1 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 7:130,842,526...130,851,530
Ensembl chr 7:130,844,138...130,851,529
|
|
G |
Gpr132 |
G protein-coupled receptor 132 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of GPR132 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 6:131,924,061...131,943,327
Ensembl chr 6:131,924,160...131,942,168
|
|
G |
Gpr139 |
G protein-coupled receptor 139 |
decreases expression |
EXP |
lead acetate results in decreased expression of GPR139 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr 1:173,481,583...173,522,451
Ensembl chr 1:173,481,583...173,522,451
|
|
G |
Gpr155 |
G protein-coupled receptor 155 |
increases expression |
ISO |
lead acetate results in increased expression of GPR155 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr 3:58,216,422...58,270,350
Ensembl chr 3:58,216,423...58,270,275
|
|
G |
Gpr183 |
G protein-coupled receptor 183 |
increases expression |
EXP |
lead acetate results in increased expression of GPR183 mRNA |
CTD |
PMID:22641619 |
|
NCBI chr15:99,037,764...99,050,550
Ensembl chr15:99,036,367...99,050,559
|
|
G |
Gprasp1 |
G protein-coupled receptor associated sorting protein 1 |
increases expression |
ISO |
lead acetate results in increased expression of GPRASP1 mRNA |
CTD |
PMID:21829687 |
|
NCBI chr X:98,765,581...98,772,685
Ensembl chr X:98,709,841...98,772,851
|
< | |